Document:

Exhibit 4.4

 Exhibit 4.4 
 FORM OF SUBSCRIPTION AGREEMENT 
 THIS SUBSCRIPTION AGREEMENT (this
“Agreement”) is dated as of                      , 2009, and is by and between FBR CAPITAL MARKETS CORPORATION, a Virginia
corporation (the “Company”) and the undersigned party (“Purchaser”). Each of the Company and Purchaser are referred to herein individually as a “Party” and collectively as the
“Parties.” 
 RECITALS 
 WHEREAS, the Company, FBR Capital Markets & Co. (“FBR & Co.”), Watch Hill Partners LLC (“WHP”), and certain holders of the outstanding membership interests (the
“Membership Interests”) in WHP, have entered into that certain Purchase Agreement, dated as of July 29, 2009, whereby FBR & Co. has agreed to acquire all of the Membership Interests, all as more fully set forth in the
Purchase Agreement; 
 WHEREAS, Purchaser understands that the Company is offering to sell the number of shares (the “Offered
Shares”) of its common stock, par value $0.001 per share (“Company Common Stock”), set forth on Schedule I hereto to Purchaser in consideration for [•], all upon the terms and subject to conditions set forth
herein; and 
 WHEREAS, Purchaser desires to subscribe for, and the Company desires to sell to Purchaser, the Offered Shares, all upon the
terms and subject to conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants,
and agreements contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 Section 1.    Subscription for and Purchase of Company Common Stock. 
 Section
1.1    Purchase of Company Common Stock. Pursuant to the terms and subject to the conditions set forth in this Agreement, Purchaser hereby subscribes for and agrees to purchase, and the Company hereby agrees to sell to
Purchaser, at the Closing (as hereinafter defined), the Offered Shares in consideration for [•] (the “Purchase Price”). 
 Section 1.2    Sale of Company Common Stock. The sale and purchase of the Offered Shares shall take place at the Closing. The Parties agree that prior to the Closing, the Company shall update Schedule I
hereto to indicate the exact number of Offered Shares to be issued at Closing, as determined in accordance with the terms of the Purchase Agreement. Notwithstanding anything in this Agreement to the contrary, Purchaser understands and agrees that
the Company shall have no obligation to (a) issue, sell or deliver any shares of Company Common Stock to any person who is a resident of a jurisdiction in which such issuance, sale or delivery to such person would constitute a violation of the
securities or “blue sky” laws of such jurisdiction, or (b) sell to Purchaser the Offered Shares, unless the transactions contemplated by the Purchase Agreement shall be consummated concurrently with the sale and purchase of the
Offered Shares. 

 Section 1.3    The Closing. Subject to the terms and conditions hereof, the
closing of the transactions contemplated hereby (the “Closing”) shall occur on the date of the “Closing” under the Purchase Agreement (the “Closing Date”). On the Closing Date, Purchaser shall deliver to
the Company the Purchase Price in exchange for which the Company shall issue to Purchaser the Offered Shares, and the Company shall deliver to Purchaser (or Purchaser’s representative) a certificate or certificates representing the Offered
Shares so purchased and issued. The Closing shall take place at the offices of the Company at 1001 Nineteenth Street North, Arlington, Virginia 22209 or at such other place as the Parties may mutually agree. 
 Section 2.    Representations and Warranties of the Company. The Company represents and warrants to Purchaser as follows: 
 Section 2.1    The Company is duly incorporated, validly existing, and in good standing under the laws of the Commonwealth of
Virginia. The Company has all requisite power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by the
Company, and the performance by the Company of its obligations hereunder, and the consummation of the transactions contemplated hereby have been duly authorized by all corporate or other action of the Company. This Agreement has been duly and
validly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Purchaser, constitutes legal, valid and binding obligations of the Company enforceable against the Company in accordance with its terms,
subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting or relating to creditor’s rights generally and subject, as to enforceability, to general principles of equity.

 Section 2.2    Except for such filings, if any, as are required to be made in connection with the Purchase Agreement,
no approval or consent from any governmental authority or any other person is necessary to be obtained, made or given by the Company in connection with the execution and delivery by the Company of this Agreement. None of the execution, delivery, or
performance of this Agreement by the Company will (a) conflict with or result in a breach of any provision in the Company’s certificate of incorporation or bylaws, (b) result in a violation or breach of any terms or provisions of, or
constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, modification, cancellation or acceleration or loss of material benefits) under any of the terms, conditions or provisions of any
material contract, agreement, note, bond, mortgage, or instrument to which the Company is a party or by which the Company is bound, or (c) violate any permit, license, franchise, or law applicable to the Company or to which the Company or any
of its assets or properties may be subject to or bound, except in the case of (b) or (c), any violation, breach or default that would not have or would not reasonably be expected to have a material adverse effect on the Company. 
 Section 2.3    The Company’s authorized capital stock consists of 300,000,000 shares of Company Common Stock and 100,000,000
shares of preferred stock, par value $0.001 per share. As of July 27, 2009 (without giving effect to the consummation of the transactions contemplated by the Purchase Agreement or the Closing hereunder), 63,087,329 shares of Company Common
Stock are issued and outstanding. Except as described in the two preceding sentences, and except as disclosed in the reports, schedules, registration statements and definitive proxy statements filed by the Company with the Securities and Exchange
Commission (the “Company SEC Documents”), no other class of equity securities or 

  

 2 

 
other securities or rights of any kind of the Company is authorized, issued or outstanding. All shares of issued and outstanding Company Common Stock are
duly authorized, validly issued, fully paid and nonassessable and have not been issued in violation of any preemptive rights created by statute, the Company’s organizational documents or any agreement to which the Company is a party or by which
it is bound. 
 Section 2.4    There are not outstanding any bonds, debentures, notes or other indebtedness of the
Company having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which holders of Company Common Stock may vote (“Voting Company Debt”). Except as disclosed in the
Company SEC Documents, there are not any options, warrants, rights, convertible or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock based performance units, commitments, agreements, arrangements or
undertakings of any kind to which the Company is a party or by which it is bound (i) obligating the Company to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or
any security convertible or exercisable for or exchangeable into shares of capital stock or other equity interests in the Company or any Voting Company Debt, (ii) obligating the Company to issue, grant, extend or enter into any such option,
warrant, call, right, security, commitment, agreement, arrangement or undertaking, or (iii) that give any person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights occurring to holders
of Company Common Stock. Except as disclosed in the Company SEC Documents, the Company is not a party to or bound by and, there are no, restrictions upon, or voting trusts, proxies or other agreements or understandings of any kind with respect to,
the voting, purchase, issuance, redemption, acquisition or transfer of, or the declaration or payment of any dividend or distribution on, Company Common Stock. Any contractual preemptive rights with respect to the Company Common Stock have been
waived by the holders thereof with respect to the transactions contemplated hereby. 
 Section 2.5    Effective upon the
Closing, Purchaser shall acquire record and beneficial ownership of the Offered Shares. When issued and delivered by the Company in accordance with the terms hereof, the Offered Shares shall be fully paid and non-assessable, and entitle Purchaser to
all rights that may become attached to such Offered Shares following the Closing. 
 Section 2.6    Neither the Company
nor any person or entity acting on behalf of the Company has offered to sell any of the Offered Shares to Purchaser by means of any form of general solicitation or general advertising, including, without limitation, (i) any advertisement,
article, notice or other communication published in any newspaper, magazine or similar media, or broadcast over television or radio, and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general
advertising. 
 Section 3.    Representations and Warranties of Purchaser. Purchaser represents and warrants to the Company as
follows: 
  

 3 

 Section 3.1    If Purchaser is an institutional investor, Purchaser is duly
organized, validly existing, and in good standing under the laws of the jurisdiction of its organization. Purchaser has all requisite power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and to
consummate the transactions contemplated hereby. The execution and delivery of this Agreement by Purchaser, and the performance by Purchaser of its obligations hereunder, and the consummation of the transactions contemplated hereby have been duly
authorized by all corporate or other action of Purchaser. This Agreement has been duly and validly executed and delivered by Purchaser and, assuming the due authorization, execution and delivery by the Company, constitutes legal, valid and binding
obligations of Purchaser enforceable against Purchaser in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting or relating to creditor’s rights
generally and subject, as to enforceability, to general principles of equity. 
 Section 3.2    No approval or consent
from any governmental authority or any other person is necessary to be obtained, made or given by Purchaser in connection with the execution and delivery by Purchaser of this Agreement. None of the execution, delivery, or performance of this
Agreement by Purchaser will (a) if Purchaser is an institutional investor, conflict with or result in a breach of any provision in Purchaser’s organizational documents (including, without limitation, certificates or articles of
incorporation, organization or formation, bylaws, limited liability company agreements, limited partnership agreements, and trust agreements), (b) result in a violation or breach of any terms or provisions of, or constitute (with or without due
notice or lapse of time or both) a default (or give rise to any right of termination, modification, cancellation or acceleration or loss of material benefits) under any of the terms, conditions or provisions of any material contract, agreement,
note, bond, mortgage, or instrument to which Purchaser is a party or by which Purchaser is bound, or (c) violate any permit, license, franchise, or law applicable to Purchaser or to which Purchaser or any of its assets or properties may be
subject to or bound, except in the case of (b) or (c), any violation, breach or default that would not have or would not reasonably be expected to have a material adverse effect on Purchaser. 
 Section 3.3    If Purchaser is an individual, Purchaser is at least 21 years of age, a citizen or permanent resident of the United
States of America, and is of sufficient legal capacity to execute and deliver this Agreement, perform Purchaser’s obligations hereunder, and to consummate the transactions contemplated hereby. 
 Section 3.4    Purchaser is domiciled in, or is a resident of, the state set forth in Purchaser’s notice address on the
signature page hereto. 
 Section 3.5    Purchaser understands that the Offered Shares will be issued in reliance upon
Rule 506 of Regulation D under the Act or in reliance upon another exemption from the registration requirements of the Act. Purchaser is an “accredited investor” as such term is defined in Rule 501 of Regulation D under the Act.

 Section 3.6    The Offered Shares are being purchased for Purchaser’s own account for investment and are not
being purchased for the account of any other person. The Offered Shares are not being purchased with a view to the distribution thereof or with any intention of distributing or reselling any of the Offered Shares, and any transfer of such shares by
Purchaser 

  

 4 

 
will be made only in compliance with the provisions of this Agreement and all applicable federal and state securities laws, including, without limitation,
the Securities Act of 1933, as amended (the “Act”). 
 Section 3.7    In order to adequately evaluate
the merits and risks of an investment in the Company, Purchaser has had an opportunity to (i) ask questions and receive answers from the Company and its representatives concerning the Company and Purchaser’s investment therein, and
(ii) obtain any additional information which Purchaser has requested with respect to the Company and Purchaser’s investment therein. Purchaser has had the opportunity to verify the accuracy of any information that has been provided to
Purchaser. Purchaser has evaluated the merits and risks of investing in the Company and has determined that the Company is a suitable investment for Purchaser. 
 Section 3.8    Purchaser understands that Purchaser (a) is subscribing for the Offered Shares without being furnished any literature or prospectus in connection with the offering other than,
the Purchase Agreement, this Agreement, and certain other written information and materials related to the consummation of the transactions contemplated by the Purchase Agreement, (b) that all of the foregoing information and materials have
been provided by the Company, (c) that none of such information has been reviewed by the Securities and Exchange Commission (“SEC”) or by the securities administrator of the state or jurisdiction of the Company or
Purchaser’s residence, and (d) neither the SEC nor any other securities administrator has recommended or endorsed the purchase of the Offered Shares or made any determination as to the fairness of the provisions of this Agreement.

 Section 3.9    Purchaser’s purchase of the Offered Shares is consistent, in both nature and amount, with
Purchaser’s overall investment program and financial condition, and Purchaser’s financial condition is such that Purchaser can afford to bear the economic risk of holding the Offered Shares for an indefinite period of time and can afford
to suffer a complete loss of Purchaser’s investment in the Offered Shares. 
 Section 3.10    Purchaser’s
overall commitment to investments that are not readily marketable is not disproportionate to Purchaser’s net worth, and Purchaser’s purchase of the Offered Shares will not cause such overall commitment to become excessive. 
 Section 3.11    Purchaser has adequate means of providing for Purchaser’s current needs and, if applicable, possible personal
contingencies. Purchaser has no need for liquidity of the Offered Shares and has no reason to anticipate any change in Purchaser’s circumstances, financial or otherwise, which might cause or require any sale or distribution of the Offered
Shares. 
 Section 3.12    Purchaser has knowledge and experience in financial and business matters that will enable
Purchaser (alone or with a purchaser representative) to utilize the information made available to Purchaser in connection with the offering of the Offered Shares to evaluate the merits and risks of such offering. 
 Section 3.13    Purchaser understands that the purchase of the Offered Shares is a speculative investment that involves a high degree
of risk of loss of the investment therein, that 

  

 5 

 
there are substantial restrictions on the transferability of the Offered Shares because there will be no public market for the Offered Shares, and that it
may not be possible for Purchaser to liquidate the investment in the Offered Shares in case of emergency, if at all. 
 Section
3.14    All information which Purchaser has provided to the Company including, but not limited to, Purchaser’s financial position and Purchaser’s knowledge of financial and business matters is true, correct and complete
in all material respects as of the date of execution of this Agreement. Purchaser undertakes to provide promptly to the Company written notice of any material changes in Purchaser’s financial position which occur prior to the Closing, and such
information will be true, correct and complete as of the date given. Purchaser understands that the Company will rely upon the representations contained herein in determining the suitability of Purchaser as a purchaser of the Offered Shares and in
issuing and selling Company Common Stock to Purchaser. 
 Section 3.15    Purchaser represents and warrants that
(a) Purchaser understands and has taken cognizance of all the risk factors related to the purchase of the Offered Shares and, other than those expressly set forth in Section 2, no representations or warranties by the Company or any
representative, affiliate, or promoter of the Company have been made to Purchaser or Purchaser’s representatives concerning the Offered Shares, the Company, its financial condition, prospects, or other matters, and no representations and
warranties other than those expressly set forth in Section 2 are being relied upon by Purchaser; (b) in making Purchaser’s decision to purchase the Offered Shares hereby subscribed for, Purchaser has relied upon independent
investigations made by Purchaser and, to the extent believed by Purchaser to be appropriate, Purchaser’s representatives, including professional, financial, tax and other advisors retained specifically to advise Purchaser, and Purchaser has
consulted, or has had the opportunity to consult, independent counsel selected by Purchaser; and (c) Purchaser has been given the opportunity to examine all documents and to ask questions of, and has received answers from, the Company and its
representatives concerning the terms and conditions of the purchase of the Offered Shares and to obtain any additional information that Purchaser deems necessary or material to make an informed decision and, in Purchaser’s judgment, Purchaser
has received sufficient information to evaluate the merits and risks of purchase of the Offered Shares. 
 Section
3.16    Purchaser acknowledges that the Company will review the representations, warranties and covenants contained in this Agreement without making any independent investigation, and that, notwithstanding any other provision of
this Agreement, the representations, warranties and covenants made by Purchaser shall survive the execution and delivery of this Agreement and the purchase of the Offered Shares. 
 Section 3.17    Purchaser acknowledges that the purchase of the Offered Shares may involve tax consequences, and Purchaser confirms
that Purchaser is not relying on any statements or representations of the Company with respect to the tax and other economic considerations of an investment in the Offered Shares, and Purchaser acknowledges that it may be advisable for Purchaser to
retain professional advisors to evaluate the federal, state and local tax and other economic considerations of an investment in the Offered Shares. Purchaser acknowledges that Purchaser is solely responsible for Purchaser’s own tax liability
that may arise as a result of this investment or the transactions contemplated by this Agreement. 
  

 6 

 Section 4.    Closing Conditions. 
 Section 4.1    Conditions to Obligations of the Company to Close. The obligation of the Company to issue the Offered Shares to
Purchaser is subject to the satisfaction prior to or concurrently with the Closing of the following conditions: 
  

	 	(a)	The representations and warranties of Purchaser contained herein shall be true and correct in all material respects at and as of the Closing as though then made;

  

	 	(b)	Purchaser shall have satisfied each of Purchaser’s obligations hereunder; 

  

	 	(c)	The transactions contemplated by the Purchase Agreement shall be consummated concurrently with the Closing; and 

  

	 	(d)	The Company shall have received the Purchase Price. 

 Section 4.2    Conditions to Obligations of Purchaser to Close. The obligation of Purchaser to acquire the Offered Shares as provided herein is subject to the satisfaction prior to or concurrently with the Closing
of the following conditions: 
  

	 	(a)	The representations and warranties of the Company contained herein shall be true and correct in all materials respects at and as of the Closing as though then made;

  

	 	(b)	The Company shall have satisfied each of its obligations hereunder; 

  

	 	(c)	The transactions contemplated by the Purchase Agreement shall be consummated concurrently with the Closing; and 

  

	 	(d)	Purchaser shall have received a certificate representing the Offered Shares. 

 Section 5.    Transferability. Purchaser agrees not to transfer or assign this Agreement, or any of Purchaser’s interests herein, and understands further that this Agreement is not
assignable by operation of law, without the Company’s consent. Purchaser agrees and acknowledges that he will not, directly or indirectly, offer, transfer, sell, assign, pledge, hypothecate or otherwise dispose of any of the Offered Shares, or
solicit any offers to purchase or otherwise acquire or take a pledge of any of the Offered Shares, unless such offer, transfer, sale, assignment, pledge, hypothecation or other disposition complies with the provisions of this Agreement and
(i) any such transfer, sale, assignment, pledge, hypothecation or other disposition is pursuant to an effective registration statement under the Act, and has been registered under all applicable state securities or “blue sky” laws, or
(ii) Purchaser shall have furnished the Company with an opinion of counsel, which opinion and counsel shall be reasonably satisfactory to the Company and its counsel, to the effect that no such registration is required because of the
availability of an exemption from registration under the securities or “blue sky” laws. 
 Section
6.    Offered Shares Unregistered. Purchaser has been advised by the Company, and Purchaser hereby acknowledges and agrees, that (a) the Offered Shares have not been registered 

  

 7 

 
under the Act and have not been qualified or registered under the securities laws of any states or other jurisdictions, and the Offered Shares are being
offered and sold in reliance on exemptions from the registration requirements of the Act and all applicable securities laws; (b) the Offered Shares must be held indefinitely and Purchaser may not sell, transfer, or otherwise dispose of the
Offered Shares but must continue to bear the economic risk of the investment in the Offered Shares unless the offer and sale of such Offered Shares is subsequently registered under the Act and all applicable state securities laws or an exemption
from such registration is available and Purchaser shall have furnished the Company with an opinion of counsel, which opinion and counsel shall be reasonably satisfactory to the Company and its counsel, to such effect; (c) if any of the Offered
Shares may be disposed of without registration under the Act in reliance on Rule 144 promulgated under the Act, such disposition can be made only in limited amounts in accordance with the terms and conditions of such Rule; (d) if the Rule 144
exemption is not available, public offer or sale without registration will require compliance with Regulation A or the availability of an exemption under the Act; (e) a notation shall be made in the appropriate records of the Company indicating
that the Offered Shares are subject to restrictions on transfer and “stop-transfer” instructions will be issued to the Company’s transfer agent with respect to any attempted transfer of the Offered Shares in violation of the terms of
this Agreement; and (f) the following restrictive legend shall be placed on the certificate(s) representing the Offered Shares: 
 THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ( THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE. ACCORDINGLY, SUCH SHARES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED
STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS, EXCEPT THAT SUCH SHARES MAY BE OFFERED, RESOLD, PLEDGED OR OTHERWISE TRANSFERRED (A) TO THE COMPANY OR A SUBSIDIARY THEREOF, (B) PURSUANT TO A REGISTRATION STATEMENT THAT HAS
BEEN DECLARED EFFECTIVE UNDER THE SECURITIES ACT, (C) FOR SO LONG AS THE SHARES ARE ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE SECURITIES ACT, IN A TRANSACTION COMPLYING WITH THE REQUIREMENTS OF RULE 144A TO A PERSON OR ENTITY WHO THE
TRANSFEROR BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (“QIB”) THAT PURCHASES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QIB AND TO WHOM NOTICE IS GIVEN THAT THE OFFER, RESALE, PLEDGE OR TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A,
(D) PURSUANT TO OFFERS AND SALES TO NON-U.S. PERSONS THAT OCCUR OUTSIDE THE UNITED STATES OR (E) PURSUANT TO ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, SUBJECT IN EACH OF THE FOREGOING CASES TO
ANY REQUIREMENT OF LAW THAT THE DISPOSITION OF THE TRANSFEROR’S PROPERTY BE AT ALL TIMES WITHIN THE TRANSFEROR’S CONTROL AND SUBJECT TO COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY JURISDICTION. THE FOREGOING RESTRICTIONS ON
TRANSFER WILL NOT APPLY SUBSEQUENT TO THE DATE THAT IS TWO YEARS AFTER THE LATER OF THE DATE OF ORIGINAL ISSUANCE AND THE LAST DATE ON WHICH THE COMPANY OR ANY AFFILIATE OF THE 

  

 8 

 
COMPANY (OR ANY PREDECESSOR THERETO) WAS THE OWNER OF SUCH SHARES, PROVIDED THAT THE COMPANY AND THE TRANSFEROR OTHERWISE MEET THE REQUIREMENTS OF RULE
144(K) UNDER THE SECURITIES ACT. THE TRANSFEROR AND THE TRANSFEREE SHALL FURNISH TO THE COMPANY AND THE TRANSFER AGENT SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER INFORMATION SATISFACTORY AS EITHER OF THEM MAY REASONABLY REQUEST TO CONFIRM THAT A
TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH THE FOREGOING RESTRICTIONS. AS USED HEREIN, “UNITED STATES” AND “U.S.
PERSON” HAVE THE MEANINGS GIVEN TO THEM BY REGULATION S UNDER THE SECURITIES ACT. 
 Section 7.    Certain
Registration Rights. The Company agrees that, within 60 days of the Closing Date, it will (a) either (i) file a registration statement on Form S-3 with the SEC to include all Elected Shares (as defined below), or (ii) include all
Elected Shares on any other registration statement that Parent intends to file with the SEC, and (b) use commercially reasonable efforts to have such registration statement declared effective by the SEC as soon as practicable, and maintain the
effectiveness of such registration statement at least until the earlier of (x) the first anniversary of the date of effectiveness of such registration statement, or (y) the date on which all Elected Shares included on such registration
statement have been sold. No later than three Business Days (as such term is defined in the Purchase Agreement) prior to the date that the Company intends to file a registration statement referenced in the immediately preceding sentence, the Company
shall provide written notice of such intent to Purchaser. Purchaser shall have the right to elect to include all or a portion of the Offered Shares in such registration statement, which right will expire on 12:00 p.m. Arlington, Virginia time on the
day prior to the date that Parent intends to file such registration statement. The shares of Company Common Stock elected by Purchaser to be included on a registration statement to be filed by the Company in accordance with the provisions of this
Section 7 are referred to herein as “Elected Shares.” The Parties agree that the Company will not have any obligation to make more than one offer to include any of the Offered Shares on a registration statement to be
filed with the SEC. The Parties agree that, except as provided in this Section 7, no other registration rights will be granted by the Company in connection with the transactions contemplated by this Agreement. The Parties agree that the
Company will not have any obligation to engage in any underwritten offering or participate in road show activities with respect to any registration statement referenced in this Section 7. The Parties agree as set forth on Exhibit
A with respect to any registration statement filed in accordance the terms of this Section 7 that includes any Elected Shares. 
 Section 8.    Rule 144. The Company will file the reports required to be filed by it under the Act and/or the Securities Exchange Act of 1934, as amended (the “Exchange Act”) to the extent
required from time to time to enable Purchaser to sell the Offered Shares without registration under the Act within the limitation of the exemptions provided by (i) Rule 144 under the Act, as such Rule may be amended from time to time, or
(ii) any similar rule or regulation hereafter adopted by the SEC. If any Offered Shares are to be disposed of in accordance with Rule 144 under the Act or otherwise, Purchaser shall promptly notify the Company of such intended 

  

 9 

 
disposition and deliver to the Company at or prior to the time of such disposition such documentation as the Company may reasonably request in connection
with such sale and, in the case of a disposition in accordance with Rule 144, an executed copy of Form 144 required to be filed with the SEC (if required by Rule 144). Notwithstanding anything contained in this Section 8 to the contrary,
the Company may deregister any of its securities under the Exchange Act if it is then permitted to do so pursuant to the Exchange Act. Nothing in this Section 8 shall be deemed to limit in any manner the restriction on sales of the
Offered Shares otherwise contained in this Agreement. 
 Section 9.    Indemnification. 
 Section 9.1    Indemnification by Purchaser. Purchaser acknowledges and understands the meaning and legal consequences of the
representations and warranties contained in this Agreement, and hereby agrees to indemnify and hold harmless the Company and each affiliate, officer, director, promoter and agent of the Company and any person or entity controlling the Company from
and against any and all loss, damage or liability due to or arising out of a breach of any representation or warranty of Purchaser contained in this Agreement. The representations and warranties contained herein shall survive the delivery of the
Offered Shares contemplated hereby. 
 Section 9.2    Indemnification by the Company. The Company acknowledges and
understands the meaning and legal consequences of the representations and warranties contained in this Agreement, and hereby agrees to indemnify and hold harmless Purchaser and each affiliate, officer, director, promoter and agent of Purchaser and
any person or entity controlling Purchaser from and against any and all loss, damage or liability due to or arising out of a breach of any representation or warranty of the Company contained in this Agreement. The representations and warranties
contained herein shall survive the delivery of the Offered Shares contemplated hereby. 
 Section 10.    Miscellaneous.

 Section 10.1    Notices. All notices and other communications required or permitted hereunder will be in writing
and, unless otherwise provided in this Agreement, will be deemed to have been duly given when delivered in person or sent via facsimile (with confirmation), or one Business Day after having been sent by a nationally recognized overnight courier
service to the appropriate Party at the address specified below: 
  

	 	(a)	If to the Company, to: 

 FBR Capital Markets Corporation

 1001 Nineteenth Street North 
 Arlington, Virginia 22209 
 Attention: Executive Vice President and General Counsel 
 Facsimile: (703) 469-1140 
  

	 	(b)	If to Purchaser, to the address specified on the signature page hereto; 

  

 10 

 or to such other address or addresses or facsimile number as any such Party may from time to time designate as to itself
by like notice. 
 Section 10.2    Successors and Assigns; No Third-Party Beneficiaries. No Party may assign any
of its rights under this Agreement without the prior written consent of the other Party. This Agreement will apply to, be binding in all respects upon, and inure to the benefit of the successors and permitted assigns of the Parties. Nothing
expressed or referred to in this Agreement will be construed to give any person other than the Parties any legal or equitable right, remedy or claim under or with respect to this Agreement. This Agreement and all of its provisions and conditions are
for the sole and exclusive benefit of the Parties and their successors and assigns. 
 Section 10.3    Entire
Agreement. This Agreement, which includes the Schedules hereto, supersedes any other agreement, whether written or oral, that may have been made or entered into by any Party relating to the matters contemplated by this Agreement and constitutes
the entire agreement by and among the Parties with respect to the subject matter hereof. 
 Section
10.4    Amendments, Supplements, and Modifications. This Agreement may be amended, supplemented, or modified only by a written agreement signed by the Party against whom the enforcement of such amendment, supplement, or
modification is sought. 
 Section 10.5    Governing Law; Jurisdiction. This Agreement shall be governed by and
construed under the Laws of the Commonwealth of Virginia (without regard to the conflict of law principles thereof). Each of the Parties hereby irrevocably submits to the jurisdiction of any state or federal court located in the Commonwealth of
Virginia with respect to the interpretation and enforcement of the provisions of this Agreement, the documents referred to herein, and in respect of the transactions contemplated hereby, and waives any objection as to venue laid therein. Each Party
hereby consents to and grants any such court jurisdiction over the person of such Party and agrees that mailing of process or other papers in connection with any such action or proceeding in the manner provided in Section 10.1 or in such
other manner as may be permitted by applicable law shall be valid and sufficient service thereof. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR
INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 Section
10.6    Execution in Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument, and
such counterpart signature pages may be delivered by means of facsimile or other electronic transmission. 
 Section
10.7    Severability. Wherever possible, each provision hereof shall be interpreted in such a manner as to be effective and valid under applicable law. In case any one or more of the provisions contained herein shall, for
any reason, be held to be invalid, illegal or unenforceable in any respect, such provision or provisions shall be ineffective to the extent, but only to the extent, of such invalidity, illegality or unenforceability, and the remainder of the
provisions of this Agreement shall remain in full force and effect and shall in no way be affected, 

  

 11 

 
impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereunder are not affected in any manner materially
adverse to any Party. Upon such a determination, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a reasonably acceptable manner so that the transactions
contemplated hereunder may be consummated as originally contemplated to the fullest extent possible. 
 Section
10.8    Publicity. Except as otherwise required by applicable Law or the rules and regulations of any national securities exchange, no Party shall issue any press release or otherwise make any public statement with respect
to the transactions contemplated by this Agreement without prior consultation with and the consent (not to be unreasonably withheld or delayed) of the other Parties. 
 Section 10.9    Rights Cumulative; Waiver. The rights and remedies of Purchaser and the Company under this Agreement shall be cumulative and not exclusive of any rights or remedies that they
would otherwise have hereunder or at law or in equity or by statute, and no failure or delay by such Party in exercising any right or remedy shall impair any such right or remedy or operate as a waiver of such right or remedy, nor shall any single
or partial exercise of any power or right preclude its other or further exercise or the exercise of any other power or right. The waiver by any Party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any
preceding or succeeding breach and no failure by either Party to exercise any right or privilege hereunder shall be deemed a waiver of such Party’s rights or privileges hereunder or shall be deemed a waiver of such Party’s rights to
exercise the same at any subsequent time or times hereunder. 
 Section 10.10    Rights to Negotiate. Nothing in
this Agreement shall be deemed to restrict or prohibit the Company from purchasing any or all of the Offered Shares from Purchaser at any time upon such terms and conditions and at such price as may be mutually agreed upon between the Company and
Purchaser. 
 Section 10.11    Recapitalizations, Exchanges, Etc., Affecting Company Common Stock. The provisions
of this Agreement shall apply, to the full extent set forth herein with respect to the Company Common Stock, and to any and all shares of capital stock of the Company or any successor or assign of the Company (whether by merger, consolidation, sale
of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution of Company Common Stock, by reason of any stock dividend, stock split, stock issuance, reverse stock split, combination, recapitalization,
reclassification, merger, consolidation or otherwise. 
 [Signature Page Follows] 
  

 12 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.

  

			
	 PURCHASER
  
 If an individual:

	
	 
	Name:                                      
                                         
           
	Notice address:
	
	 
	
	 
	
	 
	Attention:                                      
                                         
    
	Facsimile:                                      
                                         
    
	
	If an entity:
		
	By:	 	 
		 	Name of
entity:                                        
                        
		 	Jurisdiction of
organization:                                       
 
		 	Name of
signatory:                                       
                  
		 	Title:                                      
                                         
     
	Notice address:
	
	 
	
	 
	
	 
	Attention:                                      
                                         
    
	Facsimile:                                      
                                         
    
	
	FBR CAPITAL MARKETS CORPORATION
		
	By:	 	 
		 	Name:
		 	Title:

 SCHEDULE I 
 Offered Shares 
  

			
	 Purchaser
	 	 Number of Offered Shares

 EXHIBIT A 
 (to Subscription Agreement) 
 Agreements Regarding a Registration Statement that Includes Elected Shares

 With respect to a registration statement (the “Registration Statement”) filed in accordance with the terms of
Section 7 of the Agreement that includes the Elected Shares, the Parties agree as follows: 
 1.    Black-Out Period. 
 (a)    Subject to the provisions of this
Section 1 of Exhibit A and a good faith determination by a majority of the Board of Directors of the Company that it is in the best interests of the Company to suspend the use of the Registration Statement, following the effectiveness of
the Registration Statement (and the filings with any international, federal or state securities commissions), the Company, by written notice to Purchaser, may direct Purchaser to suspend sales of the Elected Shares pursuant to the Registration
Statement for such times as the Company reasonably may determine is necessary and advisable (but in no event for more than an aggregate of 90 days or more than 45 days in any consecutive 90-day period), if any of the following events shall occur:
(i) the majority of the Board of Directors of the Company shall have determined in good faith that (A) the offer or sale of any Elected Shares would materially impede, delay or interfere with any proposed material financing, offer or sale
of securities, acquisition, corporate reorganization or other material transaction involving the Company, (B) after the advice of counsel, the sale of Elected Shares pursuant to the Registration Statement would require disclosure of non-public
material information not otherwise required to be disclosed under applicable law, and (C) (x) the Company has a bona fide business purpose for preserving the confidentiality of such transaction, (y) disclosure would have a material
adverse effect on the Company or the Company’s ability to consummate such transaction, or (z) renders the Company unable to comply with SEC requirements, in each case under circumstances that would make it impractical or inadvisable to
promptly amend or supplement the Registration Statement on a post-effective basis, as applicable; or (ii) the majority of the Board of Directors of the Company shall have determined in good faith, after the advice of counsel, that it is
required by law, rule or regulation or that it is in the best interests of the Company to supplement the Registration Statement or file a post-effective amendment to the Registration Statement in order to incorporate information into the
Registration Statement for the purpose of (1) including in the Registration Statement any prospectus required under Section 10(a)(3) of the Act; (2) reflecting in the prospectus (the “Prospectus”) included in the
Registration Statement any facts or events arising after the effective date of the Registration Statement (or of the most-recent post-effective amendment) that, individually or in the aggregate, represents a fundamental change in the information set
forth therein; or (3) including in the Prospectus any material information with respect to the plan of distribution not disclosed in the Registration Statement or any material change to such information. Upon the occurrence of any such
suspension, the Company shall use its best efforts to cause the Registration Statement to promptly amend or supplement the Registration Statement on a post-effective basis or to take such action as is necessary to make resumed use of the 

  

 A - 1 

 
Registration Statement compatible with the Company’s best interests, as applicable, so as to permit Purchaser to resume sales of the Elected Shares as
soon as possible, and in no event shall any such suspension exceed the time periods specified in the first sentence of this Section 1(a) of Exhibit A. 
 (b)    In the case of an event that causes the Company to suspend the use of the Registration Statement pursuant to
Section 1(a) of this Exhibit A (a “Suspension Event”), the Company shall give written notice (a “Suspension Notice”) to Purchaser to suspend sales of the Elected Shares and such notice shall state
generally the basis for the notice and that such suspension shall continue only for so long as the Suspension Event or its effect is continuing and the Company is using its best efforts and taking all reasonable steps to terminate suspension of the
use of the Registration Statement as promptly as possible. Purchaser shall not effect any sales of the Elected Shares pursuant to such Registration Statement (or such filings) at any time after it has received a Suspension Notice from the Company
and prior to receipt of an End of Suspension Notice (as defined below). If so directed by the Company, Purchaser will deliver to the Company (at the expense of the Company) all copies other than permanent file copies then in Purchaser’s
possession of the Prospectus at the time of receipt of the Suspension Notice. Purchaser may recommence effecting sales of the Elected Shares pursuant to the Registration Statement (or such filings) following further written notice to such effect (an
“End of Suspension Notice”) from the Company, which End of Suspension Notice shall be given by the Company to Purchaser in the manner described above promptly following the conclusion of any Suspension Event and its effect.

 (c)    Notwithstanding any provision herein to the contrary, if the Company shall give a Suspension
Notice pursuant to this Section 1 of Exhibit A, the Company agrees that it shall extend the period of time during which the Registration Statement shall be maintained effective pursuant to this Agreement by the number of days during the
period from the date of receipt by Purchaser of the Suspension Notice to and including the date of receipt by Purchaser of the End of Suspension Notice and copies of the Prospectus as supplemented or amended necessary to resume sales. 
 2.    Indemnification and Contribution. 
 (a)    The Company agrees to indemnify and hold harmless (i) Purchaser, (ii) each person, if any, who
controls (within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act), Purchaser (any person referred to in this clause (ii), a “Controlling Person”), and (iii) the respective officers,
directors, partners, members, employees, representatives and agents of any such person or any Controlling Person (any such person referred to in clause (i), (ii) or (iii), a “Purchaser Indemnitee”), to the fullest extent
lawful, from and against any and all losses, claims, damages, judgments, actions, out-of-pocket expenses, and other liabilities (the “Liabilities”), including without limitation and as incurred, reimbursement of all reasonable costs
of investigating, preparing, pursuing or defending any claim or action, or any investigation or proceeding by any governmental agency or body, commenced or threatened, including the reasonable fees and expenses of counsel to any Purchaser
Indemnitee, joint or several, directly or indirectly related to, based upon, arising out of or in connection with any untrue 

  

 A - 2 

 
statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus (as amended or supplemented if the Company
shall have furnished to such Purchaser Indemnitee any amendments or supplements thereto), or any preliminary prospectus or any other document used to sell the Elected Shares, or any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, except insofar as such Liabilities arise out of or are based upon (i) any untrue statement or
omission or alleged untrue statement or omission made in reliance upon and in conformity with information relating to any Purchaser Indemnitee furnished to the Company in writing by such Purchaser Indemnitee expressly for use therein, or
(ii) any untrue statement contained in or omission from a preliminary prospectus if a copy of the Prospectus (as then amended or supplemented, if the Company shall have furnished to or on behalf of Purchaser any amendments or supplements
thereto) was not sent or given by or on behalf of Purchaser to the person asserting any such Liabilities who purchased any Elected Shares, if the Prospectus (or the Prospectus as amended or supplemented) is required by law to be sent or given at or
prior to the written confirmation of the sale of such Elected Shares to such person and the untrue statement contained in or omission from such preliminary prospectus was corrected in the Prospectus (or the Prospectus as amended or supplemented).
The Company shall notify Purchaser promptly of the institution, threat or assertion of any claim, proceeding (including any governmental investigation), or litigation of which it shall have become aware in connection with the matters addressed by
this Agreement which involves the Company or a Purchaser Indemnitee. The indemnity provided for herein shall remain in full force and effect regardless of any investigation made by or on behalf of any Purchaser Indemnitee. 
 (b)    In connection with the Registration Statement, Purchaser agrees to indemnify and hold harmless the Company,
each person who controls the Company within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act and the respective partners, directors, officers, members, representatives, employees and agents of such person or
Controlling Person to the same extent as the foregoing indemnity from the Company to each Purchaser Indemnitee, but only with respect to untrue statements or omissions or alleged untrue statements or omissions made solely in reliance upon
information relating to such Purchaser Indemnitee furnished to the Company in writing by such Purchaser Indemnitee expressly for use in the Registration Statement or the Prospectus, any amendment or supplement thereto or any preliminary prospectus.

 (c)    If any suit, action, proceeding (including any governmental or regulatory investigation), claim
or demand shall be brought or asserted against any person in respect of which indemnity may be sought pursuant to Section 2(a) or Section 2(b) of this Exhibit A, such person (the “Indemnified Party”), shall
promptly notify the person against whom such indemnity may be sought (the “Indemnifying Party”), in writing of the commencement thereof (but the failure to so notify an Indemnifying Party shall not relieve it from any liability
which it may have under this Section 2 of Exhibit A, except to the extent the Indemnifying Party is materially prejudiced by the failure to give notice), and the Indemnifying Party, upon request of the Indemnified Party, shall retain
counsel reasonably satisfactory to the Indemnified Party to represent the Indemnified Party and 

  

 A - 3 

 
any others the Indemnifying Party may reasonably designate in such proceeding and shall pay the reasonable fees and expenses actually incurred by such
counsel related to such proceeding. Notwithstanding the foregoing, in any such proceeding, any Indemnified Party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified
Party, unless (i) the Indemnifying Party and the Indemnified Party shall have mutually agreed in writing to the contrary, (ii) the Indemnifying Party failed within a reasonable time after notice of commencement of the action to assume the
defense and employ counsel reasonably satisfactory to the Indemnified Party, (iii) the Indemnifying Party and its counsel do not actively and vigorously pursue the defense of such action, or (iv) the named parties to any such action
(including any impleaded parties), include both such Indemnified Party and the Indemnifying Party, or any affiliate of the Indemnifying Party, and such Indemnified Party shall have been reasonably advised by counsel that, either (x) there may
be one or more legal defenses available to it which are different from or additional to those available to the Indemnifying Party or such affiliate of the Indemnifying Party, or (y) a conflict may exist between such Indemnified Party and the
Indemnifying Party or such affiliate of the Indemnifying Party (in which case the Indemnifying Party shall not have the right to assume nor direct the defense of such action on behalf of such Indemnified Party, it being understood, however, that the
Indemnifying Party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the fees and expenses
of more than one separate firm of attorneys (in addition to any local counsel), for all such Indemnified Parties, which firm shall be designated in writing by those Indemnified Parties who sold a majority of the Elected Shares sold by all such
Indemnified Parties and any such separate firm for the Company, the directors, the officers and such control persons of the Company as shall be designated in writing by the Company). The Indemnifying Party shall not be liable for any settlement of
any proceeding effected without its written consent, which consent shall not be unreasonably withheld, but if settled with such consent or if there is a final judgment for the plaintiff, the Indemnifying Party agrees to indemnify any Indemnified
Party from and against any loss or liability by reason of such settlement or judgment. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending or threatened proceeding in respect
of which any Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such proceeding. 
 (d)    If the indemnification provided for in
Section 2(a) or Section 2(b) of this Exhibit A is for any reason held to be unavailable to an Indemnified Party in respect of any Liabilities referred to therein (other than by reason of the exceptions provided therein) or is
insufficient to hold harmless a party indemnified thereunder, then each Indemnifying Party under such Sections, in lieu of indemnifying such Indemnified Party thereunder, shall contribute to the amount paid or payable by such Indemnified Party as a
result of such Liabilities (i) in such proportion as is appropriate to reflect the relative benefits of the Indemnified Party on the one hand and the Indemnifying Party(ies) on the other in connection with the statements or omissions that
resulted in such Liabilities, or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such 

  

 A - 4 

 
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Indemnifying
Party(ies) and the Indemnified Party, as well as any other relevant equitable considerations. The relative fault of the Company on the one hand and any Purchaser Indemnitees on the other shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by such Purchaser Indemnitees and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 (e)    The Parties agree that it would not be just and equitable if contribution pursuant to this Section 2 of Exhibit A were determined by pro rata allocation (even if such Indemnified Parties were
treated as one entity for such purpose), or by any other method of allocation that does not take account of the equitable considerations referred to in Section 2(d) of this Exhibit A. The amount paid or payable by an Indemnified Party as
a result of any Liabilities referred to Section 2(d) of this Exhibit A shall be deemed to include, subject to the limitations set forth above, any reasonable legal or other expenses actually incurred by such Indemnified Party in
connection with investigating or defending any such action or claim. For purposes of this Section 2 of Exhibit A, each person, if any, who controls (within the meaning of Section 15 of the Act or Section 20(a) of the Exchange
Act) Purchaser shall have the same rights to contribution as Purchaser, as the case may be, and each person, if any, who controls (within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act) the Company, and each
officer, director, partner, employee, representative, agent or manager of the Company shall have the same rights to contribution as the Company. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action,
suit or proceeding against such party in respect of which a claim for contribution may be made against another party or parties, notify each party or parties from whom contribution may be sought, but the omission to so notify such party or parties
shall not relieve the party or parties from whom contribution may be sought from any obligation it or they may have under this Section 2 of Exhibit A or otherwise, except to the extent that any party is materially prejudiced by the
failure to give notice. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act), shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 
 (f)    The indemnity and contribution agreements contained in this Section 2 of Exhibit A will be in
addition to any liability which the Indemnifying Parties may otherwise have to the Indemnified Parties. 
  

 A - 5Employment Agreement

 Exhibit 10.1 
 EMPLOYMENT AGREEMENT 
 This EMPLOYMENT AGREEMENT (the “Agreement”) by and between
CareFusion Corporation, a Delaware corporation (the “Company”) and David L. Schlotterbeck (the “Executive”) is effective as of the 31 day of August 2009 (the “Agreement”). 
 IT IS HEREBY AGREED AS FOLLOWS: 
 1.
Effective Date. The effective date of this Agreement (the “Effective Date”) shall be the effective date of the spin-off of the Company from Cardinal Health, Inc. 
 2. Employment Period. The Company hereby agrees to employ the Executive, and the Executive hereby agrees to serve the Company, subject to the
terms and conditions of this Agreement, for the period commencing on the Effective Date and ending on the date of the Company’s annual meeting of stockholders next following the third anniversary of the Effective Date (the “Employment
Period”), unless prior to such date the employment of the Executive is terminated pursuant to this Agreement. At least one-hundred and eighty (180) days before the end of the Employment Period, the parties will discuss either succession
planning or the potential for extension of this Agreement. If the Executive remains employed with the Company after the end of the Employment Period without an extension of the Agreement, he will be an employee “at-will.” 
 3. Terms of Employment. (a) Position and Duties. (i) During the Employment Period, the Executive shall serve as Chairman of the
Board of Directors and Chief Executive Officer of the Company with such authority, duties and responsibilities as are customarily assigned to such positions. The Executive shall report directly to the Board of Directors of the Company (the
“Board”). The Executive’s services shall be performed in San Diego, California. 
 (ii) During the Employment Period, and
excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive agrees to devote his full business attention and time to the business and affairs of the Company and, to the extent necessary to discharge the
responsibilities assigned to the Executive hereunder, to use the Executive’s reasonable best efforts to perform faithfully and efficiently such responsibilities. During the Employment Period, it shall not be a violation of this Agreement for
the Executive to (A) serve on the board of directors of, or own shares or hold options to purchase shares in, Virtual Radiologic, Inc., (B) subject to the approval of the Board (which shall not be unreasonably withheld), serve on other
corporate, civic or charitable boards or committees, (C) deliver lectures, fulfill speaking engagements or teach at educational institutions, (D) manage personal investments, so long as such activities do not materially interfere with the
performance of the Executive’s responsibilities as an employee of the Company in accordance with this Agreement, and (E) own shares in companies that are not competitors of the Company. 
 (b) Compensation (i) Base Salary. During the Employment Period, the Company shall pay Executive an annual base salary (“Annual
Base Salary”) at a rate of not less than $1,000,000 payable in accordance with the Company’s normal payroll policies. The Executive’s Annual Base Salary shall be reviewed, and may be increased but not decreased, at least annually by
the 

  

 1 

 
Human Resources and Compensation Committee of the Board (the “Committee”) pursuant to its normal performance review policies for senior executives.
Any increase in Annual Base Salary shall not serve to limit or reduce any other obligation to the Executive under this Agreement. Annual Base Salary shall not be reduced after any such increase and the term Annual Base Salary as utilized in this
Agreement shall thereafter refer to Annual Base Salary as so increased. 
 (ii) Annual Bonus. With respect to each fiscal year ending
during the Employment Period, the Executive shall be eligible to receive an annual cash bonus (“Annual Bonus”) determined and paid at the sole discretion of the Company pursuant to terms and conditions of the Company bonus plan for which
the Executive is then eligible. Executive’s Annual Bonus target under this Agreement for any fiscal year (the fiscal year’s “Target Bonus”) shall be an amount equal to 120% of Executive’s Annual Base Salary. The actual
Annual Bonus, which could be higher or lower than the Target Bonus, shall be based on the attainment of performance objectives as determined no later than 90 days after the beginning of the fiscal year by the Committee in consultation with the
Executive, and shall be paid, subject to any effective deferral elections that may be made by the Executive pursuant to any deferred compensation plans that the Company may maintain, within two and one-half months following the end of the fiscal
year for which the Annual Bonus is earned. Notwithstanding anything herein to the contrary, to the extent permitted or required by governing law, the Committee shall have discretion to require the Executive to repay to the Company the amount of any
Annual Bonus to the extent the Committee determines that such bonus was not actually earned by the Executive due to (A) the amount of such payment was based on the achievement of financial results that were subsequently the subject of a
material accounting restatement that occurs within three years of such payment (except in the case of a restatement due to a change in accounting policy or simple error); (B) the Executive has engaged in fraud, gross negligence or intentional
misconduct; or (C) the Executive has deliberately misled the market or the Company’s stockholders regarding the Company’s financial performance. 
 (iii) Retention Award. The Executive shall receive a retention award (“Retention Award”) consisting of restricted stock units (“RSUs”) and stock options (“Options”) to be granted
in 2009 on the date that annual equity awards are granted to employees (the “Grant Date”). The Retention Award will be determined as follows, subject to the following terms and conditions: 
 A. RSUs. The number of RSUs granted will equal two million dollars ($2 million), divided by the closing price of the Company’s common stock
on the Grant Date. 
 B. Options. The number of Options granted will be determined by dividing two million dollars ($2 million) by
the option value per share of the Company’s common stock (as determined by the Committee, and with the volatility determined by the Company using the average volatility of similar medical technology companies). The Options will be granted with
an exercise price equal to the closing price of the Company’s common stock on the Grant Date. 
  

 2 

 C. Vesting. The Retention Awards will vest and become exercisable in the case of Options, and
payable in the case of RSUs, as follows; provided, however, that, except as provided below, the Executive must remain employed through the Employment Period (but not thereafter) and continue to comply with the restrictive
covenants set forth in Section 7 of this Agreement (the “Covenants”) as of each applicable vesting date: 
 1. One-third of
the Retention Award will vest on the third anniversary of the Effective Date; 
 2. One-third of the Retention Award will vest on the fourth
anniversary of the Effective Date; and 
 3. One-third of the Retention Award will vest on the fifth anniversary of the Effective Date.

 In the event that the Executive’s employment is terminated, prior to the third anniversary of the Effective Date, by the Company
without Cause, or the Executive terminates employment with the Company for Good Reason, then the outstanding unvested Retention Awards will become fully vested on the Executive’s Date of Termination but will not be exercisable or payable at
that time. Rather, the vested Retention Awards will become exercisable in the case of Options, and payable in the case of RSUs, in equal installments on the Date of Termination (as hereinafter defined) and the first and second anniversaries of the
Executive’s Date of Termination, without regard to compliance with the Covenants. 
 All outstanding unvested Retention Awards will
become fully vested and exercisable in the case of Options, and payable in the case of RSUs, upon Executive’s death or Disability. 
 All vested and unvested Retention Awards will be immediately forfeited and terminate if Executive is terminated by the Company for Cause. All unexercised and unpaid Retention Awards will be immediately forfeited and terminate if Executive
does not comply with the Covenants during the Restricted Period that begins upon Executive’s termination of employment at or after the end of the Employment Period. 
 D. RSU Settlement. Vested RSUs are paid in fully tradable shares of the Company’s common stock within 30 days following the date on which they become payable in accordance with the foregoing provisions.

 E. Option Exercises. Vested Options granted as part of the Retention Award that are or become exercisable remain exercisable for
the remaining term of the Option, subject to the provisions of Section 3(b)(iii)C above. 
 F. Award Agreements Control. The
terms and conditions of the Retention Award will be substantially in the form set forth in separate equity award agreements attached hereto as Exhibit A and Exhibit B. In the event of any discrepancy between this
Agreement and the provisions of the applicable award agreements, the provisions of the applicable award agreements 

  

 3 

 
other than price, vesting and exercisability provisions will control; provided however, to the extent the provisions of the applicable award agreements that
relate to price, vesting or exercisability are more favorable to Executive than those in this Agreement, such provisions of the applicable award agreements will control. 
 (iv) Annual Equity Grants. The Executive is eligible to receive annual equity-based grants (“Annual Equity Grants”) during the Employment Period as determined in the discretion of the Committee. The
terms and conditions of Annual Equity Grants (other than exercisability and forfeiture, which are described below) will be established by the Committee at the time of grant and set forth in separate award agreements; in the event of any discrepancy
between this Agreement and the provisions of the applicable award agreements, the provisions of the applicable award agreements will control. 
 Notwithstanding the foregoing, the Company will grant to Executive an Annual Equity Grant in 2009, on the date on which annual employee grants are made, in addition to the Retention Award, with a total value of seven million dollars ($7
million) on the date of grant. The Committee will determine the type of awards comprising the Annual Equity Grant in its discretion. The number of Options will be determined by dividing that portion of the seven million dollars ($7 million) which
the Committee determines will be granted in Options by the option value per share of the Company’s common stock (as determined by the Committee, and with the volatility determined by the Company using the average volatility of similar medical
technology companies). 
 All Annual Equity Grants will be subject to the following terms and conditions: 
 A. Vesting, Exercisability, and Forfeiture. Because the Executive is eligible for retirement under the Company’s 2009 Long-Term Incentive
Plan (the “LTIP”), all Annual Equity Grants will be fully vested upon grant, but the Options will be subject to restrictions on exercisability as described in the applicable award agreements, and RSUs and performance share units
(“PSUs”) will be payable as described in the applicable award agreements. 
 Notwithstanding the foregoing, 
 (i) all outstanding Annual Equity Grants that are Options will become fully exercisable upon termination of Executive’s employment by the
Company without Cause, Executive’s termination of employment with the Company for Good Reason, or Executive’s death or Disability; 
 (ii) all outstanding Annual Equity Grants that are RSUs, other than PSUs, will become payable upon termination of Executive’s employment by the Company without Cause, Executive’s termination of employment with the Company for Good
Reason, or Executive’s death or Disability and under the foregoing circumstances, PSUs will paid based on actual performance compared to target, at the same time payment of PSUs is made to other senior executives; and 
  

 4 

 (iii) all outstanding Annual Equity Grants will continue to become exercisable or payable, as
applicable, in accordance with their terms in the event of voluntary termination by the Executive without Good Reason. 
 In addition, all
outstanding Annual Equity Grants will become fully exercisable and payable upon a “Change of Control” of the Company, as defined in the LTIP, and with respect to Annual Equity Grants that are RSUs subject to Section 409A of the
Internal Revenue Code and the Treasury Regulations thereunder (“Section 409A”), provided that such “Change of Control” is also a “change in control event” as described in Section 409A. All unexercised and unpaid
Annual Equity Grants will be immediately forfeited and terminate if Executive is terminated by the Company for Cause. 
 B. Options.
Annual Equity Grants that are Options will be granted with an exercise price equal to the closing price of the Company’s common stock on the grant date. Annual Equity Grants that are Options will remain exercisable for the entire term of the
Option unless earlier forfeited and terminated as described above. 
 (v) Other Employee Benefit Plans. During the Employment Period,
the Executive and/or the Executive’s family, as the case may be, shall be eligible for participation in and shall receive all benefits under savings and retirement plans that are tax-qualified under Section 401(a) of the Internal Revenue
Code of 1986, as amended (the “Code”), in plans that are supplemental to any such tax-qualified plans, and welfare benefit plans, practices, policies and programs provided by the Company, but not any severance plan, practice, policy or
program, on a basis that is no less favorable than those generally applicable or made available to other senior executives of the Company. The Executive shall be eligible for participation in fringe benefits and perquisite plans, practices, policies
and programs (including, without limitation, expense reimbursement plans, practices, policies and programs) on a basis that is commensurate with his position and no less favorable than those generally applicable or made available to most other
senior executives of the Company. 
 (vi) Expenses. During the Employment Period, the Executive shall be entitled to receive prompt
reimbursement for all expenses incurred by the Executive in accordance with the Company’s policies for its senior executives. 
 (vii)
Use of Aircraft. During the Employment Period, the Executive, and his immediate family when accompanied by Executive, shall be entitled to personal use of Company aircraft, subject to availability, up to a value of $100,000 per fiscal year of
the Company determined in accordance with the SEC’s rules for valuing personal use of corporate aircraft for purposes of proxy disclosure, at no cost and without reimbursement to the Company; provided however, that income will be imputed to
Executive for tax purposes pursuant to Company policy as established by the Board or Committee and consistent with applicable tax regulations. Any use in excess of the dollar value limit described above must be approved by the Committee in advance.

 (viii) Vacation. During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the plans,
policies, programs and practices of the Company as in effect with respect to other senior executives of the Company. 
  

 5 

 (c) Indemnification. Company shall indemnify and hold harmless Executive in accordance with the
provisions of the CareFusion Officer and Director Indemnification Agreement attached hereto as Exhibit C. 
 (d) Rabbi
Trust. Executive may defer compensation pursuant to the CareFusion Corporation Deferred Compensation Plan, as it may be amended from time to time, and deferrals shall be held in a rabbi trust, subject to the Company’s policies with respect
to maintaining a rabbi trust for such purpose. 
 4. Termination of Employment. (a) Death or Disability. The
Executive’s employment shall terminate automatically upon the Executive’s death during the Employment Period. If the Company determines in good faith that the Disability of the Executive has occurred during the Employment Period (pursuant
to the definition of Disability set forth below), it may provide the Executive with written notice after such determination in accordance with Section 11(b) of this Agreement of its intention to terminate the Executive’s employment. In
such event, the Executive’s employment with the Company shall terminate effective on the 30th day after receipt of such notice by the Executive (the “Disability Effective Date”), provided that, within thirty (30) days
after such receipt, the Executive shall not have returned to full-time performance of the Executive’s duties. For purposes of this Agreement, other than with respect to vesting and payment of RSUs subject to Section 409A,
“Disability” shall mean the absence of the Executive from the Executive’s duties with the Company on a full-time basis for not less than 120 consecutive days (or an aggregate period of not less than 180 days) as a result of incapacity
due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive’s legal representative. For purposes of vesting and payment
of RSUs, to the extent necessary to comply with Section 409A, “Disability” shall have the meaning provided in Section 409A. 
 (b) Cause. The Company may terminate the Executive’s employment during the Employment Period for Cause. For purposes of this Agreement, “Cause” shall mean: 
 (i) the willful and continued failure of the Executive to perform substantially the Executive’s duties with the Company (other than any such
failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to the Executive by the Board or its representative, which specifically identifies the manner in which the Board
believes that the Executive has willfully and continuously failed to perform substantially the Executive’s duties with the Company; 
 (ii) the willful engaging by the Executive in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company or its affiliates; 
 (iii) conviction of a felony; or 
 (iv) a
material breach of Section 7 of this Agreement subject to the cure provisions of Section 7(a). 
 For purposes of this Section 4(b), no act or
failure to act on the part of the Executive shall be considered “willful” unless it is done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive’s act or omission was in the best
interests of the Company. Any act, or failure to act, based upon express authority given pursuant to a resolution duly adopted by the 

  

 6 

 
Board with respect to such act or omission or based upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be
done, by the Executive in good faith and in the best interests of the Company. The cessation of employment of the Executive shall not be deemed to be for Cause unless and until there shall have been delivered to the Executive a copy of a resolution
duly adopted by the affirmative vote of not less than three-quarters (3/4) of the entire membership of the Board not including the Executive at a meeting of the Board called and held for such purpose (after reasonable notice is provided to the
Executive and the Executive is given an opportunity, together with counsel, to be heard before the Board), finding that, in the good faith opinion of the Board, the Executive engaged in the conduct described in Section 4(b) (i), (ii), or
(iv) above, and specifying the particulars thereof in detail. 
 (c) Good Reason. The Executive’s employment may be
terminated by the Executive for Good Reason. For purposes of this Agreement, “Good Reason” shall mean, in the absence of a written consent of the Executive: 
 (i) the assignment to the Executive of any duties materially inconsistent in any respect with the Executive’s position (including status, offices, titles and reporting requirements), authority, duties or
responsibilities as contemplated by Section 3(a) of this Agreement, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose any action not
taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Executive; 
 (ii) any failure
by the Company to comply with any of the provisions of Sections 3(a) or 3(b) of this Agreement, other than a failure not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Executive;

 (iii) the Company requiring the Executive to be based at any office or location more than 10 miles from that provided in
Section 3(a)(i) hereof, provided that reasonable travel required in connection with Executive’s reporting relationships and responsibilities to the Board shall not be deemed a breach hereof; 
 (iv) any purported termination by the Company of the Executive’s employment otherwise than as expressly permitted by this Agreement; 
 (v) any failure by the Company to comply with Section 9(c) of this Agreement; or 
 (vi) any failure of the Board or shareholders of the Company to elect Executive as a member of the Board, or the removal of Executive from the Board for
reasons other than those justifying or requiring such removal under the other provisions of this Agreement. 
  

 7 

 (d) Notice of Termination. Any termination by the Company for Cause, or by the Executive for Good
Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 11(b) of this Agreement. For purposes of this Agreement, a “Notice of Termination” means a written notice which
(i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s
employment under the provision so indicated and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more than thirty (30) days after
the giving of such notice). The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the Executive or the
Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder. 
 (e) Date of Termination. “Date of Termination” means (i) if the Executive’s employment is terminated by the Company for Cause,
or by the Executive with or without Good Reason, the date of receipt of the Notice of Termination or any later date specified therein within thirty (30) days of such notice, as the case may be, (ii) if the Executive’s employment is
terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date on which the Company notifies the Executive of such termination and (iii) if the Executive’s employment is terminated by reason of
death or Disability, the Date of Termination shall be the date of death of the Executive or the Disability Effective Date, as the case may be. 
 (f) Resignation. Upon termination of the Executive’s employment for any reason, the Executive agrees to resign, as of the Date of Termination, to the extent applicable, from any positions that the Executive holds with the
Company and its affiliated companies, the Board (and any committees thereof) and the Board of Directors (and any committees thereof) of any of the affiliated companies. 
 5. Obligations of the Company upon Termination. (a) Good Reason; Other Than for Cause or Disability. If, during the Employment Period, (i) the Company shall terminate the Executive’s
employment other than for Cause or Disability, or (ii) the Executive shall terminate employment for Good Reason: 
 (i) Subject to the
execution by the Executive and the Company of a release of claims in favor of the Company, substantially in the form attached hereto as Exhibit D, the Company shall pay to the Executive the aggregate of the following amounts:

 A. The sum of (1) the Executive’s accrued but unpaid Annual Base Salary and any accrued vacation pay through the
Date of Termination, (2) the Executive’s business expenses that have not been reimbursed by the Company as of the Date of Termination that were incurred by the Executive prior to the Date of Termination in accordance with the applicable
Company policy, and (3) the Executive’s Annual Bonus earned for the fiscal year immediately preceding the fiscal year in which the Date of Termination occurs if such bonus has not been paid as of the Date of Termination (the sum of the

  

 8 

 
amounts described in clauses (1) through (3), shall be hereinafter referred to as the “Accrued Obligations”). The Accrued Obligations shall be
paid in a lump sum on the Date of Termination of Executive’s employment; provided that notwithstanding the foregoing, if the Executive has made an irrevocable election under any deferred compensation arrangement subject to
Section 409A to defer any portion of the Annual Bonus described above, then for all purposes of this Section 5, such deferral election, and the terms of the applicable arrangement shall apply, and such portion shall not be considered as
part of the “Accrued Obligations” but shall instead be an “Other Benefit” (as defined below). 
 B. A
pro rata Annual Bonus for the year of termination (“Pro Rata Bonus”), based upon the actual achievement of the performance objectives as determined by the Committee for the fiscal year of termination, to be paid in a lump sum at the
same time as the Annual Bonus is paid to other senior executives of the Company, but in no event later than two and one-half months following the end of the fiscal year in which occurs the Date of Termination; provided that notwithstanding
the foregoing, if the Executive has made an irrevocable election under any deferred compensation arrangement subject to Section 409A to defer any portion of the Annual Bonus described above, then for all purposes of this Section 5, such
deferral election, and the terms of the applicable arrangement shall apply, and such portion shall not be considered as part of the “Accrued Obligations” but shall instead be an “Other Benefit” (as defined below). 
 (ii) The Company shall pay as severance to the Executive an amount equal to twice the sum of (1) the Executive’s Annual Base Salary and
(2) the Target Bonus in respect of the fiscal year of termination or, if the Target Bonus has not been established for such fiscal year, in respect of the immediately preceding fiscal year, payable in twenty-four (24) equal monthly
installments commencing on the later of (A) thirty (30) days following the expiration of any review and revocation period set forth in the release of claims required by this Section 5, or (B) the first business day after the date
that is six (6) months following the Executive’s Separation from Service (as defined in Section 10). 
 (iii) The Company
shall pay the premiums for COBRA continuation coverage for the Executive and his eligible dependents through the earliest of: (a) the Executive’s coverage under a health insurance plan of another employer; or (b) eighteen
(18) months following the Date of Termination. 
 (iv) To the extent not theretofore paid or provided, the Company shall timely pay or
provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive under any plan, program, policy or practice or contract or agreement of the Company and its affiliated companies
through the Date of Termination (such other amounts and benefits shall be hereinafter referred to as the “Other Benefits”), in accordance with the terms of such plan, program, policy or practice or contract or agreement. As used in this
Agreement, the term “affiliated companies” shall include any company controlled by, controlling or under common control with the Company. 
  

 9 

 Notwithstanding the foregoing or anything else to the contrary in this Agreement, payments under this
Section 5(a) shall be subject to the provisions of Section 10, including but not limited to the provisions of paragraph (f) thereof. 
 (b) Death. If the Executive’s employment is terminated by reason of the Executive’s death during the Employment Period the Company shall have no further obligations to the Executive’s legal representatives under this
Agreement, other than for (i) payment of Accrued Obligations, (ii) the timely payment or provision of Other Benefits in accordance with their terms, (iii) payment of the Pro Rata Bonus, and (iv) vesting, exercisability, and
payment of the awards as described in Sections 3(b)(iii) and 3(b)(iv). Accrued Obligations shall be paid to the Executive’s estate or beneficiary, as applicable, in a lump sum in cash within thirty (30) days of the Date of Termination and
the Pro Rata Bonus shall be paid to the Executive’s estate or beneficiary, as applicable, on the date specified in Section 5(a)(i)(B). In the event of the Executive’s death after his termination of employment, but prior to the receipt
of all amounts to which he is entitled under this Agreement, all remaining amounts to which he is entitled shall be paid to his estate or beneficiary, as applicable. 
 (c) Disability. If the Executive’s employment is terminated by the Company by reason of the Executive’s Disability during the Employment Period, the Company shall have no further obligations to the
Executive, other than for (i) payment of Accrued Obligations, (ii) the timely payment or provision of Other Benefits in accordance with their terms, (iii) payment of the Pro Rata Bonus, and (iv) vesting, exercisability, and
payment of the awards as described in Sections 3(b)(iii) and 3(b)(iv). Accrued Obligations shall be paid to the Executive in a lump sum in cash on the Date of Termination and the Pro Rata Bonus shall be paid to the Executive on the date specified in
Section 5(a)(i)(B). Notwithstanding the foregoing or anything else to the contrary in this Agreement, payments under this Section 5(c) shall be subject to the provisions of Section 10, including but not limited to the provisions of
paragraph (f) thereof. 
 (d) Cause; Other than for Good Reason. If the Executive’s employment shall be terminated by the
Company for Cause or the Executive terminates his employment without Good Reason during the Employment Period, the Company shall have no further obligations to the Executive other than the obligation to pay and provide to the Executive the Accrued
Obligations through the Date of Termination to the extent theretofore unpaid. 
 (e) Retirement. Notwithstanding anything herein to
the contrary, in the event the Executive terminates employment due to his retirement (i.e., termination of employment on or after the attainment of age 65), the Executive shall be entitled to payment of the Pro Rata Bonus in Section 5(a)(i)(B).

 6. Full Settlement. The Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its
obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against the Executive or others. In no event shall the Executive be obligated to seek other
employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall not be reduced whether or not the Executive obtains other employment. The Company
agrees to 

  

 10 

 
pay (within thirty (30) days following the Company’s receipt of an invoice from the Executive) at any time from the Effective Date through he
Executive’s remaining lifetime, (or, if longer, through the 20th anniversary of
the Effective Date), to the full extent permitted by law, all legal fees and expenses which the Executive may reasonably incur as a result of any contest by either party (including, as the case may be, the Company, any of its affiliates or their
respective predecessors, successors or assigns, or the Executive, his estate, beneficiaries or their respective successors and assigns) of the validity or enforceability of, or liability under, any provision of this Agreement (including as a result
of any contest by the Executive about the amount of any payment pursuant to this Agreement); plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Code, if the Executive
prevails on any material claim made by him, and disputed by the Company under the terms of this Agreement. 
 7. Covenants.
(a) Introduction. The parties acknowledge that the provisions and covenants contained in this Section 7 are ancillary and material to this Agreement and that the limitations contained herein are reasonable in geographic and temporal
scope and do not impose a greater restriction or restraint than is necessary to protect the goodwill and other legitimate business interests of the Company. The parties also acknowledge and agree that the provisions of this Section 7 do not
adversely affect the Executive’s ability to earn a living in any capacity that does not violate the covenants contained herein. The parties also acknowledge that before Executive shall be determined to have breached any provision or covenant
contained in this Section 7, Executive shall have been given notice of any such alleged breach and been given forty-five (45) days after receipt of such notice of such breach to cure or remedy any such breach that is reasonably susceptible
of cure or remedy. 
 (b) Confidential Information. The Executive shall hold in a fiduciary capacity for the benefit of the Company
and all of its subsidiaries, partnerships, joint ventures, limited liability companies, and other affiliates (collectively, the “CareFusion Group”), all secret or confidential information, knowledge or data relating to the CareFusion Group
and its businesses (including, without limitation, any proprietary and not publicly available information concerning any processes, methods, trade secrets, intellectual property, research secret data, costs, names of users or purchasers of their
respective products or services, business methods, operating or manufacturing procedures, or programs or methods of promotion and sale) that the Executive has obtained or obtains during the Executive’s employment by the CareFusion Group and
that is not public knowledge (other than as a result of the Executive’s violation of this Section 7(b)) (“Confidential Information”). The Executive shall not communicate, divulge or disseminate Confidential Information at any
time during or after the Executive’s employment and/or service as a consultant with the CareFusion Group, except with prior written consent of a corporate officer of Company, or as otherwise required by law or legal process. All records, files,
memoranda, reports, customer lists, drawings, plans, documents and the like that the Executive uses, prepares or comes into contact with during the course of the Executive’s employment shall remain the sole property of the Company and/or the
CareFusion Group, as applicable, and shall be turned over to the applicable CareFusion Group company upon termination of the Executive’s employment. 
  

 11 

 (c) Non-Recruitment of CareFusion Group Employees, etc. Executive understands and agrees that any
information regarding Company employees is confidential and constitutes trade secrets. In recognition of the confidential nature of information regarding Company employees, Executive agrees that he shall not, at any time during the Restricted Period
(as defined in this Section 7(c)), without the prior written consent of the Company, engage in the following conduct (a “Solicitation”): (i) directly or indirectly, contact, solicit, or recruit (whether as an employee, officer,
director, agent, consultant, or independent contractor) any person who was or is at any time during the previous twelve months an employee, representative, officer or director of the CareFusion Group for the purpose of offering them employment by
any other entity, business or individual; or (ii) take any action to encourage or induce any employee, representative, officer or director of the CareFusion Group to cease their relationship with the CareFusion Group for any reason. A
“Solicitation” does not include any recruitment of employees within or for the CareFusion Group. The “Restricted Period” means the period of the Executive’s employment with the CareFusion Group and the additional period
ending on (i) in the event of a termination of employment prior to the end of the Employment Period, the second anniversary of the Date of Termination, or (ii) in the event of a termination of employment on or after the end of the
Employment Period, the second anniversary of the end of the Employment Period. 
 (d) Non-Solicitation of Business. Executive
acknowledges and agrees that Company’s customers and any information regarding Company’s customers is confidential and constitutes trade secrets. In recognition of the confidential and trade secret nature of information regarding
Company’s customers, Executive agrees that during the Restricted Period, the Executive shall not (either directly or indirectly or as an officer, agent, employee, partner or director of any other company, partnership or entity) solicit on
behalf of any competitor of the CareFusion Group the business of (i) any customer of the CareFusion Group at the time of the Executive’s employment or Date of Termination, or (ii) any potential customer of the CareFusion Group which
the Executive knew to be an identified, prospective purchaser of services or products of the CareFusion Group. 
 (e) Employment by
Competitor. During the Restricted Period, the Executive shall not invest in (other than in a publicly traded company with a maximum investment of no more than 1% of outstanding shares), counsel, advise, or be otherwise engaged or employed by,
any entity or enterprise that competes with the CareFusion Group, by developing, manufacturing or selling any product or service of a type, respectively, developed, manufactured or sold by the CareFusion Group. 
  

 12 

 (f) No Disparagement. 
 (i) The Executive and the Company shall at all times refrain from taking actions or making statements, written or oral, that (A) denigrate,
disparage or defame the goodwill or reputation of Executive or the CareFusion Group, as the case may be, or any of its trustees, officers, security holders, partners, agents or former or current employees and directors, or (B) are intended to,
or may be reasonably expected to, adversely affect the morale of the employees of the CareFusion Group. The Executive further agrees not to make any negative statement to third parties relating to the Executive’s employment or any aspect of the
businesses of CareFusion Group and not to make any statements to third parties about the circumstances of the termination of the Executive’s employment, or about the CareFusion Group or its trustees, directors, officer, security holders,
partners, agents or former or current employees and directors, except as may be required by a court or government body. 
 (ii) The
Executive further agrees that, following termination of employment for any reason, the Executive shall assist and cooperate with the Company with regard to any matter or project in which the Executive was involved during the Executive’s
employment with the Company, including but not limited to any litigation that may be pending or arise after such termination of employment. Further, the Executive agrees to notify the Company at the earliest reasonable opportunity of any contact
that is made by any third parties concerning any such matter or project. The Company shall not unreasonably request such cooperation of Executive and shall cooperate with the Executive in scheduling any assistance by the Executive taking into
account the Executive’s business and personal affairs and shall compensate the Executive for any lost wages or expenses associated with such cooperation and assistance. 
 (g) Inventions. All plans, discoveries and improvements, whether patentable or unpatentable, made or devised by the Executive, whether alone or
jointly with others, from the date of the Executive’s initial employment by the Company and continuing until the end of any period during which the Executive is employed by the CareFusion Group, relating or pertaining in any way to the
Executive’s employment with or the business of the CareFusion Group, shall be promptly disclosed in writing to the Secretary of the Board and are hereby transferred to and shall redound to the benefit of the Company and shall become and remain
its sole and exclusive property. The Executive agrees to execute any assignment to the Company or its nominee, of the Executive’s entire right, title and interest in and to any such discoveries and improvements and to execute any other
instruments and documents requisite or desirable in applying for and obtaining patents, trademarks or copyrights, at the expense of the Company, with respect thereto in the United States and in all foreign countries, that may be required by the
Company. The Executive further agrees, during and after the Employment Period, to cooperate to the extent and in the manner required by the Company, in the prosecution or defense of any patent or copyright claims or any litigation, or other
proceeding involving any trade secrets, processes, discoveries or improvements covered by this Agreement, but all necessary expenses thereof shall be paid by the Company. 
 (h) Acknowledgement and Enforcement. The Executive acknowledges and agrees that: (A) the purpose of the foregoing covenants is to protect the goodwill, trade secrets and other Confidential Information of
the Company; (B) because of the nature of 

  

 13 

 
the business in which the CareFusion Group is engaged and because of the nature of the Confidential Information to which the Executive has access, the
Company would suffer irreparable harm and it would be impractical and excessively difficult to determine the actual damages of the CareFusion Group in the event the Executive breached any of the covenants of this Section 7; and
(C) remedies at law (such as monetary damages) for any breach of the Executive’s obligations under this Section 7 would be inadequate. The Executive therefore agrees and consents that (X) if the Executive commits any breach of a
covenant under this Section 7 during the Restricted Period upon termination of employment at or after the end of the Employment Period, all unexercised and unpaid Retention Awards will be immediately forfeited and terminate, and (Y) if the
Executive commits any breach of a covenant under this Section 7 or threatens to commit any such breach at any time, the Company shall have the right (in addition to, and not in lieu of, any other right or that may be available to it) to
temporary and permanent injunctive relief from a court of competent jurisdiction, without posting any bond or other security and without the necessity of proof of actual damage. 
 (i) Similar Covenants in Other Agreements Unaffected. The Executive may be or become subject to covenants contained in other agreements (including
but limited to stock option and restricted stock unit agreements) which are similar to those contained in this Section 7. Further, a breach of the covenants contained in this Section 7 may have implications under the terms of such other
agreements, including but not limited to a forfeiture of equity awards and long-term cash compensation. The Executive acknowledges the foregoing and understands that the covenants contained in this Section 7 are in addition to, and not in
substitution of, the similar covenants contained in any such other agreements. The Company agrees that any forfeiture or repayment obligation under any such agreement shall only be imposed after a determination by the Board of Directors (after
providing the Executive with reasonable notice and an opportunity to be heard with counsel) that the Executive has violated any such covenant or has willfully engaged in any other material misconduct which may be a basis for forfeiture or a
repayment obligation thereunder. 
 8. Certain Additional Payments by the Company. (a) Notwithstanding anything in this Agreement
to the contrary, in the event it shall be determined that any payment or distribution by the Company or any of its affiliates to or for the benefit of the Executive (whether paid or payable or distributed or distributable pursuant to the terms of
this Agreement or otherwise, but determined without regard to any additional payments required under this Section 8) (a “Payment”) would be subject to the excise tax imposed by Section 4999 of the Code or any interest or
penalties are incurred by the Executive with respect to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the “Excise Tax”), then the Executive shall be entitled to
receive an additional payment (a “Gross-Up Payment”) in an amount such that after payment by the Executive of all taxes (including any interest or penalties imposed with respect to such taxes), including, without limitation, any income
taxes (and any interest and penalties imposed with respect thereto) and Excise Tax imposed upon the Gross-Up Payment, but excluding any income taxes and penalties imposed pursuant to Section 409A, the Executive retains an amount of the Gross-Up
Payment equal to the Excise Tax imposed upon the Payments. 
  

 14 

 (b) Subject to the provisions of Section 8(c), all determinations required to be made under this
Section 8, including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by a nationally recognized certified public
accounting firm reasonably acceptable to the Executive as may be designated by the Company (the “Accounting Firm”) which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the
receipt of notice from the Executive that there has been a Payment, or such earlier time as is requested by the Company. All fees and expenses of the Accounting Firm shall be borne solely by the Company. Any Gross-Up Payment, as determined pursuant
to this Section 8, shall be paid by the Company to the Executive or directly to the Internal Revenue Service, in the sole discretion of the Company, within five days of the later of (i) the due date for the payment of any Excise Tax, and
(ii) the receipt of the Accounting Firm’s determination; provided, however, that in all events such payment shall be made no later than the end of the Executive’s taxable year next following the taxable year in which the Executive
remits the payment of the excise tax. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial
determination by the Accounting Firm hereunder, it is possible that Gross-Up Payments which will not have been made by the Company should have been made (“Underpayment”), consistent with the calculations required to be made hereunder. In
the event that the Company exhausts its remedies pursuant to Section 8(c) and the Executive thereafter is required to make a payment of any Excise Tax, the Accounting Firm shall determine the amount of the Underpayment that has occurred and any
such Underpayment shall be promptly paid by the Company to or for the benefit of the Executive. 
 (c) The Executive shall notify the Company
in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of the Gross-Up Payment. Such notification shall be given as soon as practicable but no later than 20 business days after the
Executive is informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such claim is requested to be paid. The Executive shall not pay such claim prior to the expiration of the 30-day period
following the date on which it gives such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If the Company notifies the Executive in writing prior to the expiration of such
period that it desires to contest such claim, the Executive shall: 
 (i) give the Company any information reasonably requested by the
Company relating to such claim, 
 (ii) take such action in connection with contesting such claim as the Company shall reasonably request in
writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company, 
 (iii) cooperate with the Company in good faith in order effectively to contest such claim, and 
 (iv)
permit the Company to participate in any proceedings relating to such claim; 
  

 15 

 provided, however, that the Company shall bear and pay directly all costs and expenses (including
additional interest and penalties) incurred in connection with such contest and shall indemnify and hold the Executive harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed
as a result of such representation and payment of costs and expenses. Without limitation on the foregoing provisions of this Section 8(c), the Company shall control all proceedings taken in connection with such contest, and, at its sole option,
may pursue or forgo any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either pay the tax claimed to the appropriate taxing authority on behalf of
the Executive and direct the Executive to sue for a refund or contest the claim in any permissible manner, and the Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction
and in one or more appellate courts, as the Company shall determine; provided, however, that, if the Company pays such claim and directs the Executive to sue for a refund, the Company shall indemnify and hold the Executive harmless, on
an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such payment or with respect to any imputed income in connection with such payment; and provided,
further, that any extension of the statute of limitations relating to payment of taxes for the taxable year of the Executive with respect to which such contested amount is claimed to be due is limited solely to such contested amount.
Furthermore, the Company’s control of the contest shall be limited to issues with respect to which the Gross-Up Payment would be payable hereunder, and the Executive shall be entitled to settle or contest, as the case may be, any other issue
raised by the Internal Revenue Service or any other taxing authority. 
 (d) If, after the receipt by the Executive of a payment by the
Company of an amount on the Executive’s behalf pursuant to Section 8(a) or 8(c), the Executive becomes entitled to receive any refund with respect to such claim, the Executive shall (subject to the Company’s complying with the
requirements of Section 8(a) or 8(c)) promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon and after taxes applicable thereto). If, after payment by the Company of an amount on the
Executive’s behalf pursuant to Section 8(a) or 8(c), a determination is made that the Executive shall not be entitled to any refund with respect to such claim and the Company does not notify the Executive in writing of its intent to
contest such denial of refund prior to the expiration of 30 days after such determination, then the amount of such payment shall offset, to the extent thereof, the amount of Gross-Up Payment required to be paid. 
 9. Successors. (a) This Agreement is personal to the Executive and without the prior written consent of the Company shall not be assignable
by the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal representatives, heirs or legatees and the Executive by written notice to the Company may designate any beneficiary with respect to any
amounts due under this Agreement upon the Executive’s death. 
 (b) This Agreement shall inure to the benefit of and be binding upon the
Company and its successors and assigns. 
  

 16 

 (c) The Company will require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it
if no such succession had taken place. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by
operation of law, or otherwise. 
 10. Code Section 409A. (a) This Agreement is intended to comply with, or otherwise be
exempt from, Section 409A. The Company and the Executive agree that they will execute any and all amendments to this Agreement permitted under applicable law as they mutually agree in good faith may be necessary to ensure compliance with the
distribution provisions of Section 409A or as otherwise needed to ensure that this Agreement complies with Section 409A. 
 (b)
Section 10(a) shall not be construed as a guarantee by the Company of any particular tax effect to the Executive under this Agreement, however. The Company shall not be liable to the Executive for any payment made under this Agreement that is
determined to result in an additional tax, penalty, or interest under Section 409A, nor for reporting in good faith any payment made under this Agreement as an amount includible in gross income under Section 409A. 
 (c) For purposes of Section 409A, the right to a series of installment payments under this Agreement shall be treated as a right to a series of
separate payments. 
 (d) With respect to any reimbursement of expenses of, or any provision of in-kind benefits to, the Executive as
specified under this Agreement, such reimbursement of expenses or provision of in-kind benefits shall be subject to the following conditions: (1) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable
year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in
Section 105(b) of the Code; (2) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was incurred; and (3) the right to reimbursement or in-kind benefits shall
not be subject to liquidation or exchange for another benefit. 
 (e) “Termination of employment,” “resignation,” or
words of similar import used in this Agreement mean, for purposes of any payments under this Agreement that are payments of deferred compensation subject to Section 409A, the Executive’s “separation from service” (as determined
in accordance with regulations promulgated under Section 409A using the default rule under such regulations) (“Separation from Service”). 
 (f) Notwithstanding anything to the contrary in this Agreement, including but not limited to Sections 5(a), 5(b), 5(c), 5(d) and 6, (i) any amounts and benefits payable hereunder which constitute deferred
compensation subject to Section 409A and would otherwise be payable or provided to the Executive under this Agreement prior to the date which is six (6) months after the Executive’s Separation from Service shall instead be paid, with
interest on any delayed payment at the applicable federal rate provided for in 

  

 17 

 
Section 7872(f)(2)(A) of the Code (“Interest”), or provided on the first business day after the date that is six (6) months following the
Executive’s Separation from Service, or, if earlier, upon the Executive’s death, and (ii) if the Executive incurs a Separation from Service prior to his Date of Termination, the date of his Separation from Service shall be deemed to
be his Date of Termination (or equivalent term) for purposes of determining the date of payment or the payment commencement date under this Agreement. Notwithstanding clause (i) of this subparagraph above, if any amount of employment taxes,
within the meaning of regulations promulgated under Section 409A, are payable prior to the six-month anniversary of the Executive’s Separation from Service, with respect to any deferred compensation amount, the Company shall utilize and be
deemed to have paid a portion of an such deferred compensation to the extent necessary for the payment of such employment taxes. If payment of any portion of the Executive’s restricted stock units is deferred pursuant to the six-month deferral
provision in clause (i) above, then (in lieu of the payment of Interest) such restricted stock units shall be treated during such six-month period, and adjusted for investment performance in the same manner, as outstanding restricted stock
units. 
 11. Miscellaneous. (a) This Agreement shall be governed by and construed in accordance with the laws of the State of
California, without reference to principles of conflict of laws. If, under any such law, any portion of this Agreement is at any time deemed to be in conflict with any applicable statute, rule, regulation or ordinance, such portion shall be deemed
to be modified or altered to conform thereto. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement constitutes the entire and only agreement of the parties with respect to the subject
matter hereof and may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives. 
 (b) All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other parties or by registered or
certified mail, return receipt requested, postage prepaid, addressed as follows: 
  

			
	If to the Executive:	  	At the most recent address
on file at the Company; with a copy to
		
		  	Mr. George L. Damoose
		  	Procopio, Cory, Hargreaves & Savitch LLP
		  	530 B Street, Suite 2100
		  	San Diego, CA 92101
		
	If to the Company:	  	CareFusion Corporation
		  	3750 Torrey View Court
		  	San Diego, California 92130
		  	Attention: General Counsel;

 or to such other address as either party shall have furnished to the other in writing in accordance herewith.
Notice and communications shall be effective when actually received by the addressee. 
  

 18 

 (c) The invalidity or unenforceability of any provision of this Agreement shall not affect the validity
or enforceability of any other provision of this Agreement. If any provision of this Agreement shall be held invalid or unenforceable in part, the remaining portion of such provision, together with all other provisions of this Agreement, shall
remain valid and enforceable and continue in full force and effect to the fullest extent consistent with the law. 
 (d) Notwithstanding any
other provision of this Agreement, the Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation. 
 (e) The Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any
right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate employment for Good Reason pursuant to Section 4(c)(i)-(v) of this Agreement, shall not be deemed to be a waiver
of such provision or right or any other provision or right of this Agreement, except as specifically provided in a written consent pursuant to Section 4(c). 
 (f) Except as otherwise expressly provided herein, from and after the Effective Time, this Agreement shall supersede any other employment, severance or change of control agreement between the parties and between the
Executive with respect to the subject matter hereof. Any provision of this Agreement that by its terms continues after the expiration of the Employment Period or the termination of the Executive’s employment shall survive in accordance with its
terms. 
 (g) The Executive hereby warrants that the Executive is free to enter into this Agreement and to perform the services described
herein. The Company hereby warrants that this Agreement and the equity awards provided hereunder have been duly authorized. 
  

 19 

 IN WITNESS WHEREOF, the Executive has hereunto set the Executive’s hand and, pursuant to the
authorization from its Board of Directors, the Company has caused this Agreement to be executed in its name on its behalf, all as of the day and year first above written. 
  

			
	 /s/ David L. Schlotterbeck

	David L. Schlotterbeck
	Date: August 31, 2009
	
	CAREFUSION CORPORATION
		
	By	 	 /s/ Michael O’Halleran

	Name:	 	Michael O’Halleran
	Title:	 	Chair, Human Resources and Compensation Committee
	Date:	 	September 2, 2009

  

 20 

 EXHIBIT A 
 CAREFUSION CORPORATION 
 RETENTION AWARD AND NONQUALIFIED STOCK OPTION AGREEMENT 
 On [date of grant] (the “Grant Date”), CareFusion Corporation, a Delaware corporation (the “Company”), has awarded to David L.
Schlotterbeck (“Awardee”), an option (the “Option”) to purchase [# of shares] shares of common stock, par value $0.01 per share, of the Company (the “Shares”) for a price of [$X.XX] per share. The Option has been
granted under the CareFusion Corporation 2009 Long-Term Incentive Plan (the “Plan”), and will include and be subject to all provisions of the Plan, which are incorporated herein by reference, and will be subject to the provisions of this
Nonqualified Stock Option Agreement (this “Agreement”). Capitalized terms used in this Agreement which are not specifically defined will have the meanings ascribed to such terms in the Plan. This Option shall vest and become exercisable in
three installments, in which one-third of the underlying Shares shall vest on each of the third, fourth and fifth anniversaries of August 31, 2009 (each a “Vesting Date” with respect to the portion of the Option scheduled to vest on
such date), subject in each case to the provisions of this Agreement, including those relating to the Awardee’s continued employment with the Company and its Affiliates (collectively, the “CareFusion Group”). This Option shall expire
on [expiration date] (the “Grant Expiration Date”). Notwithstanding the foregoing or anything in this Agreement to the contrary, in the event of a Change of Control prior to the Awardee’s Termination of Employment, the Option shall
vest in full and be fully exercisable until the Grant Expiration Date without regard to the Covenants. 
 1. Method of Exercise and
Payment of Price. 
 (a) Method of Exercise. At any time when all or a portion of the Option is exercisable under the Plan and this
Agreement, some or all of the exercisable portion of the Option may be exercised from time to time by written notice to the Company, or such other method of exercise as may be specified by the Company, including without limitation, exercise by
electronic means on the web site of the Company’s third-party equity plan administrator, which will: 
 (i) state the number of whole
Shares with respect to which the Option is being exercised; and 
 (ii) if the Option is being exercised by anyone other than Awardee, if
not already provided, be accompanied by proof satisfactory to counsel for the Company of the right of such person or persons to exercise the Option under the Plan and all Applicable Laws and regulations. 
 (b) Payment of Price. The full exercise price for the portion of the Option being exercised shall be paid to the Company as provided below:

 (i) in cash; 
 (ii) by
check or wire transfer (denominated in U.S. Dollars); 
  

 1 

 (iii) subject to any conditions or limitations established by the Administrator, other Shares which
(A) in the case of Shares acquired from the Company (whether upon the exercise of an Option or otherwise), have been owned by the Participant for more than six months on the date of surrender (unless this condition is waived by the
Administrator), and (B) have a Fair Market Value on the date of surrender equal to or greater than the aggregate exercise price of the Shares as to which said Option shall be exercised (it being agreed that the excess of the Fair Market Value
over the aggregate exercise price shall be refunded to the Awardee, with any fractional Share being repaid in cash); 
 (iv) consideration
received by the Company under a broker-assisted sale and remittance program acceptable to the Administrator; or 
 (v) any combination of
the foregoing methods of payment. 
 2. Transferability. The Option shall be transferable (I) at Awardee’s death, by Awardee
by will or pursuant to the laws of descent and distribution, and (II) by Awardee during Awardee’s lifetime, without payment of consideration, to (a) the spouse, former spouse, parents, stepparents, grandparents, parents-in-law, siblings,
siblings-in-law, children, stepchildren, children-in-law, grandchildren, nieces or nephews of Awardee, or any other persons sharing Awardee’s household (other than tenants or employees) (collectively, “Family Members”), (b) a
trust or trusts for the primary benefit of Awardee or such Family Members, (c) a foundation in which Awardee or such Family Members control the management of assets, or (d) a partnership in which Awardee or such Family Members are the
majority or controlling partners; provided, however, that subsequent transfers of the transferred Option shall be prohibited, except (X) if the transferee is an individual, at the transferee’s death by the transferee by will or pursuant to
the laws of descent and distribution, and (Y) without payment of consideration to the individuals or entities listed in subparagraphs II(a), (b) or (c), above, with respect to the original Awardee. The Administrator may, in its discretion,
permit transfers to other persons and entities as permitted by the Plan. Neither a transfer under a domestic relations order in settlement of marital property rights nor a transfer to an entity in which more than 50% of the voting interests are
owned by Awardee or Family Members in exchange for an interest in that entity shall be considered to be a transfer for consideration. Within 10 days of any transfer, Awardee shall notify the Compensation and Benefits department of the Company in
writing of the transfer. Following transfer, the Option shall continue to be subject to the same terms and conditions as were applicable immediately prior to transfer and, except as otherwise provided in the Plan or this Agreement, references to the
original Awardee shall be deemed to refer to the transferee. The events of a Termination of Employment of Awardee provided in Paragraph 3 hereof shall continue to be applied with respect to the original Awardee, following which the Option shall be
exercisable by the transferee only to the extent, and for the periods, specified in Paragraph 3. The Company shall have no obligation to notify any transferee of Awardee’s Termination of Employment with the CareFusion Group for any reason. The
conduct prohibited of Awardee in Paragraphs 5 and 6 hereof shall continue to be prohibited of Awardee following transfer to the same extent as immediately prior to transfer and the Option (or its economic value, as applicable) shall be subject to
forfeiture by the transferee and recoupment from Awardee to the same extent as would have been the case of Awardee had the Option not been transferred. Awardee shall remain subject to the recoupment provisions of Paragraphs 5 and 6 of this Agreement
and tax withholding provisions of Section 29 of the Plan following transfer of the Option. 
  

 2 

 3. Termination of Employment; Death, Disability and Retirement. 
 (a) Death or Disability. If the death or Disability of Awardee occurs prior to the vesting in full of the Option, then any unvested portion of the
Option shall vest upon and become exercisable in full from and after such death or Disability. The Option may thereafter be exercised by the Awardee, any transferee of Awardee, if applicable, or by the legal representative of the estate or by the
legatee of Awardee under the will of Awardee from the date of such death or Disability until the Grant Expiration Date. For purposes of this Agreement, “Disability” shall have the meaning ascribed to it in Section 4(a) of
Awardee’s Employment Agreement, by and between Awardee and the Company, dated as of August 31, 2009 (the “Employment Agreement”). 
 (b) Termination of Employment by Reason of a Termination without Cause or a Termination for Good Reason. If, prior to August 31, 2012, Awardee’s employment with the Company is terminated by the
Company without Cause or by Awardee for Good Reason, then any unvested portion of the Option shall immediately vest in full and one-third of the Option shall become exercisable on the Date of Termination (as defined in Section 4(e) of the
Employment Agreement); one-third of the Option shall become exercisable on the first anniversary of the Date of Termination; and one-third of the Option shall become exercisable on the second anniversary of the Date of Termination, as described in
the Employment Agreement without regard to the Covenants. For purposes of this Agreement, “Cause” and “Good Reason” shall have the meanings ascribed to them in Section 4(b) and Section 4(c), respectively, in the
Employment Agreement. 
 (c) Termination of Employment by Reason of a Termination for Cause. If there is a Termination of Employment
of Awardee by the Company for Cause, then the Administrator shall immediately cancel the Option, whether or not any portion thereof had previously vested. 
 (d) Other Termination of Employment. If, prior to August 31, 2012, a Termination of Employment of Awardee occurs by any reason other than provided in Paragraphs (a), (b) and (c) above, any
unexercised portion of the Option which has not vested on such date of Termination of Employment will automatically be forfeited. 
 4.
Restrictions on Exercise. The Option is subject to all restrictions in this Agreement and/or in the Plan. As a condition of any exercise of the Option, the Company may require Awardee or his or her transferee or successor to make any
representation and warranty to comply with any applicable law or regulation or to confirm any factual matters (including Awardee’s compliance with the terms of Paragraphs 5 and 6 of this Agreement or any employment or severance agreement
between the CareFusion Group and Awardee) reasonably requested by the Company. The Option shall not be exercisable if such exercise would involve a violation of any Applicable Law. 
 5. Covenants. As used in this Agreement, “Covenants” shall refer to Covenants as defined in Section 3(b)(iii)(C) of the Employment
Agreement. 
  

 3 

 6. Special Forfeiture/Repayment Rules. During the Restricted Period (as defined in
Section 7(c) of the Employment Agreement), Awardee agrees to comply in full with the Covenants. Except in the case of (i) a Termination of Employment of Awardee by the Company without Cause or by Awardee for Good Reason, or (ii) a
Change of Control prior to the Awardee’s Termination of Employment which causes the Option to vest in full and be fully exercisable until the Grant Expiration Date without regard to the Covenants as provided in the first paragraph of this
Agreement, if Awardee commits any breach of the Covenants during the Restricted Period, then the unexercised portion of the Option shall immediately and automatically terminate and be forfeited as described in Section 7(h) of the Employment
Agreement. 
 No provisions of this Agreement shall diminish, negate or otherwise impact any separate noncompete or other agreement
(including the Employment Agreement) to which Awardee may be a party, including, but not limited to, any certificate of compliance or similar attestation/certification signed by Awardee. Awardee acknowledges and agrees that the restrictions
contained in this Agreement are being made for the benefit of the Company in consideration of Awardee’s receipt of the Option, in consideration of employment, in consideration of exposing Awardee to the Company’s business operations and
confidential information, and for other good and valuable consideration, the adequacy of which consideration is hereby expressly confirmed. Awardee further acknowledges that the receipt of the Option and execution of this Agreement are voluntary
actions on the part of Awardee and that the Company is unwilling to provide the Option to Awardee without including the restrictions and covenants of Awardee contained in this Agreement. Further, the parties agree and acknowledge that the provisions
contained in Paragraphs 5 and 6 are ancillary to, or part of, an otherwise enforceable agreement at the time the agreement is made. 
 7.
Right of Set-Off. By accepting this Option, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as “non-qualified deferred compensation” under Section 409A of the Code by
any member of the CareFusion Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the CareFusion Group by Awardee under this
Agreement. 
 8. Withholding Tax. 
 (a) Generally. Awardee is liable and responsible for all taxes owed in connection with the exercise of the Option, regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection
with the Option. The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the exercise of the Option. The Company does not commit and is under no obligation to
structure the Option or the exercise of the Option to reduce or eliminate Awardee’s tax liability. 
 (b) Payment of Withholding
Taxes. Concurrently with the payment of the exercise price pursuant to Paragraph 1 hereof, Awardee is required to arrange for the satisfaction of the minimum amount of any domestic or foreign tax withholding obligation, whether national,
federal, state or local, including any employment tax obligation (the “Tax Withholding Obligation”) in a manner acceptable to the Company, including withholding such amounts in cash from the Awardee’s wages or other payments due to
the 

  

 4 

 
Awardee at any time, or, in lieu thereof, to retain, or sell without notice, a number of Shares sufficient to cover the Tax Withholding Obligation. The value
of any Shares retained for such purposes shall be based on the Fair Market Value, as the term is defined in the Plan, of the Shares on the date of exercise of the Option. To the extent that the Company or its Affiliate withholds any amounts in
Shares to cover the Tax Withholding Obligation, it will do so at the minimum statutory rate. Should the Company or the Affiliate withhold any amounts in cash or retains any Shares in excess of Awardee’s actual Tax Withholding Obligation, the
Company and/or Awardee’s employer will refund the excess amount to the Awardee, with any fractional Share being repaid in cash, within a reasonable period and without any interest. The Awardee authorizes the Company or the Affiliate, or their
agents (including, without limitations, any broker or bank) to withhold cash or Shares as appropriate. Awardee agrees to pay the Company and/or the Affiliate employing Awardee any amount of the Tax Withholding Obligation that is not satisfied by the
means described herein. 
 If any of the foregoing methods of collection are not allowed under Applicable Law or if Awardee fails to comply
with his or her obligations in connection with the Tax Withholding Obligation as described in this section, the Company may refuse to honor the exercise and refuse to deliver the Shares. 
 Awardee is liable and responsible for all taxes and social security owed in connection with the Option, regardless of any action the Company takes with
respect to any Tax Withholding Obligations that arise in connection with the Option. The Company does not make any representation or undertaking regarding the tax and social security treatment or the treatment of any withholding in connection with
the exercise of the Option. The Company does not commit and is under no obligation to structure the Option or the exercise of the Option to reduce or eliminate Awardee’s tax liability. 
 9. Governing Law/Venue for Dispute Resolution/Costs and Legal Fees. This Agreement shall be governed by the laws of the State of Delaware, without
regard to principles of conflicts of law, except to the extent superceded by the laws of the United States of America. The parties agree and acknowledge that the laws of the State of Delaware bear a substantial relationship to the parties and/or
this Agreement and that the Option and benefits granted herein would not be granted without the governance of this Agreement by the laws of the State of Delaware. In addition, all legal actions or proceedings relating to this Agreement shall be
brought exclusively in state or federal courts located in the State of Delaware and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts. Awardee acknowledges that the covenants contained in Paragraphs
5 and 6 of this Agreement are reasonable in nature, are fundamental for the protection of the Company’s legitimate business and proprietary interests, and do not adversely affect Awardee’s ability to earn a living in any capacity that does
not violate such covenants. The parties further agree that in the event of any violation by Awardee of any such covenants, the Company will suffer immediate and irreparable injury for which there is no adequate remedy at law. In the event of any
violation or attempted violations of the restrictions and covenants of Awardee contained in this Agreement, the CareFusion Group shall be entitled to specific performance and injunctive relief or other equitable relief, including the issuance ex
parte of a temporary restraining order, without any showing of irreparable harm or damage, such irreparable harm being acknowledged and admitted by Awardee, and 

  

 5 

 
Awardee hereby waives any requirement for the securing or posting of any bond in connection with such remedy, without prejudice to any other rights and
remedies afforded the CareFusion Group hereunder or by law. In the event that it becomes necessary for the CareFusion Group to institute legal proceedings under this Agreement, Awardee shall be responsible to the Company for all costs and reasonable
legal fees incurred by the Company with regard to such proceedings. Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and
enforceable and that comes closest to the business objectives intended by such provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement. 
 10. Action by the Administrator. The parties agree that the interpretation of this Agreement shall rest exclusively and completely within the sole
discretion of the Administrator. The parties agree to be bound by the decisions of the Administrator with regard to the interpretation of this Agreement and with regard to any and all matters set forth in this Agreement. The Administrator may
delegate its functions under this Agreement to an officer of the CareFusion Group designated by the Administrator (hereinafter the “designee”). In fulfilling its responsibilities hereunder, the Administrator or its designee may rely upon
documents, written statements of the parties or such other material as the Administrator or its designee deems appropriate. The parties agree that there is no right to be heard or to appear before the Administrator or its designee and that any
decision of the Administrator or its designee relating to this Agreement, including without limitation whether particular conduct constitutes a breach of the Covenants, shall be final and binding unless such decision is arbitrary and capricious.

 11. Prompt Acceptance of Agreement. The Option grant evidenced by this Agreement shall, at the discretion of the Administrator, be
forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee’s acceptance of this Agreement in accordance with the acceptance procedures set forth on the
Company’s third-party equity plan administrator’s web site, within 90 days of the Grant Date. 
 12. Electronic Delivery and
Consent to Electronic Participation. The Company may, in its sole discretion, decide to deliver any documents related to the Option grant under and participation in the Plan or future options that may be granted under the Plan by electronic
means. Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company,
including the acceptance of option grants and the execution of option Agreements through electronic signature. 
 13. Notices. All
notices, requests, consents and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, facsimile, nationally recognized
overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below: 
 CareFusion Corporation 
 3750 Torrey View
Court 
 San Diego, CA 92130 
 Attention: General Counsel 
 Facsimile: 858-617-2300 
  

 6 

 All notices, requests, consents and other communications required or provided under this Agreement to be delivered by the
Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid,
and will be effective upon delivery to the Awardee. 
 14. Employment Agreement. To the extent the Employment Agreement provides for
greater benefits to Awardee with respect to (i) the vesting of the Option, (ii) the exercisability of the Option or (iii) the price of the Option than provided in this Agreement or in the Plan, then the terms of the Employment
Arrangement, with respect to the vesting of the Option, the exercisability of the Option or the price of the Option, shall supersede the terms hereof to the extent permitted by the terms of the Plan. 
  

			
	CAREFUSION CORPORATION
		
	By:	 	  

	Its:	 	  

  

 7 

 ACCEPTANCE OF AGREEMENT 
 Awardee hereby: (a) acknowledges receiving a copy of the Plan, which has either been previously delivered or is provided with this Agreement, and represents that he is familiar with and understands all provisions
of the Plan and this Agreement; (b) voluntarily and knowingly accepts this Agreement and the Option granted to him under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in the Agreement
regarding the “Covenants” and “Special Forfeiture/Repayment Rules” set forth in Paragraphs 5 and 6 above; (c) acknowledges previously accepting, and voluntarily and knowingly accepts, the terms of the equity awards of the
Company and/or Cardinal Health, Inc. that Awardee received in connection with the spin-off of the Company from Cardinal Health, Inc., subject to all the provisions of the applicable equity incentive plan(s) under which the award(s) was granted; and
(d) represents that he understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement. Awardee further acknowledges
receiving a copy of the Company’s most recent annual report to stockholders and other communications routinely distributed to the Company’s stockholders and a copy of the Plan Prospectus dated [date of Plan Prospectus] pertaining to the
Plan. 
  

	
	  

	Awardee’s Signature
	
	  

	Date

  

 8 

 EXHIBIT B  
 CAREFUSION CORPORATION 
 RETENTION AWARD AND RESTRICTED STOCK UNITS AGREEMENT 
 On [grant date] (the “Grant Date”), CareFusion Corporation, a Delaware corporation (the “Company”), has awarded to David L.
Schlotterbeck (“Awardee”) [# of shares] Restricted Stock Units (the “Restricted Stock Units” or “Award”), representing an unfunded unsecured promise of the Company to deliver shares of common stock, par value $0.01 per
share, of the Company (the “Shares”) to Awardee as set forth herein. The Restricted Stock Units have been granted pursuant to the CareFusion Corporation 2009 Long-Term Incentive Plan (the “Plan”), and shall be subject to all
provisions of the Plan, which are incorporated herein by reference, and shall be subject to the provisions of this Restricted Stock Units Agreement (this “Agreement”). Capitalized terms used in this Agreement which are not specifically
defined will have the meanings ascribed to such terms in the Plan. 
 1. Vesting. The Restricted Stock Units shall vest in three
installments, in which one-third of the Restricted Stock Units shall vest on each of the third, fourth and fifth anniversaries of August 31, 2009 (each a “Vesting Date” with respect to the portion of the Restricted Stock Units
scheduled to vest on such date), subject in each case to the provisions of this Agreement, including those relating to the Awardee’s continued employment with the Company and its Affiliates (collectively, the “CareFusion Group”).
Notwithstanding the foregoing or anything in this Agreement to the contrary, in the event of a Change of Control prior to the Awardee’s Termination of Employment, the Restricted Stock Units shall vest in full without regard to the Covenants.

 2. Transferability. The Restricted Stock Units shall not be transferable. 
 3. Termination of Employment; Death, Disability and Retirement. 
 (a) General. Except as set forth below, if a Termination of Employment of Awardee occurs prior to August 31, 2012, any unvested portion of such Restricted Stock Units shall be forfeited by Awardee.

 (b) Death or Disability. If the death or Disability of Awardee occurs prior to the vesting in full of the Restricted Stock Units
then any unvested Restricted Stock Units shall immediately vest in full and shall not be forfeited. For purposes of this Agreement, “Disability” shall have the meaning ascribed to it in Section 4(a) of Awardee’s Employment
Agreement, by and between Awardee and the Company, dated as of August 31, 2009 (the “Employment Agreement”). 
 (c)
Termination of Employment by Reason of a Termination without Cause or a Termination for Good Reason. If, prior to August 31, 2012, Awardee’s employment with the Company is terminated by the Company without Cause or by Awardee for
Good Reason, then any unvested Restricted Stock Units shall immediately vest in full and shall not be forfeited, and Awardee shall receive the Shares in accordance with the provisions of Paragraph 6(b). For purposes of this Agreement,
“Cause” and “Good Reason” shall have the meanings ascribed to them in Section 4(b) and Section 4(c), respectively, in the Employment Agreement. 
  

 1 

 (d) Termination of Employment by Reason of a Termination for Cause. If there is a Termination of
Employment of Awardee by the Company for Cause, then Awardee shall forfeit all Restricted Stock Units, whether vested or unvested. 
 4.
Covenants. As used in this Agreement, “Covenants” shall refer only to Covenants as defined in Section 3(b)(iii)(C) of the Employment Agreement. 
 5. Special Forfeiture/Repayment Rules. During the Restricted Period (as defined in Section 7(c) of the Employment Agreement), Awardee agrees to comply in full with the Covenants. Except in the case of a
Termination of Employment of Awardee by the Company without Cause or by Awardee for Good Reason, if Awardee commits any breach of the Covenants during the Restricted Period, then all unpaid Restricted Stock Units shall immediately and automatically
terminate and be forfeited as described in Section 7(h) of the Employment Agreement,. 
 No provisions of this Agreement shall diminish,
negate or otherwise impact any separate noncompete or other agreement (including the Employment Agreement) to which Awardee may be a party, including, but not limited to, any certificate of compliance or similar attestation/certification signed by
Awardee. Awardee acknowledges and agrees that the restrictions contained in this Agreement are being made for the benefit of the Company in consideration of Awardee’s receipt of the Restricted Stock Units, in consideration of employment, in
consideration of exposing Awardee to the Company’s business operations and confidential information, and for other good and valuable consideration, the adequacy of which consideration is hereby expressly confirmed. Awardee further acknowledges
that the receipt of the Restricted Stock Units and execution of this Agreement are voluntary actions on the part of Awardee and that the Company is unwilling to provide the Restricted Stock Units to Awardee without including the restrictions and
covenants of Awardee contained in this Agreement. Further, the parties agree and acknowledge that the provisions contained in Paragraphs 4 and 5 are ancillary to, or part of, an otherwise enforceable agreement at the time the agreement is made.

 6. Payment. (a) Subject to the provisions of Paragraphs 4 and 5 of this Agreement and Paragraphs (b), (c), (d) and
(e) below, and unless Awardee makes an effective election to defer receipt of the Shares represented by the Restricted Stock Units, on the date of vesting of any Restricted Stock Unit, Awardee shall be entitled to receive from the Company
(without any payment on behalf of Awardee other than as described in Paragraph 10) the Shares represented by such Restricted Stock Unit within 30 days of such date. Elections to defer receipt of the Shares beyond the date of settlement provided
herein may be permitted in the discretion of the Administrator pursuant to procedures established by the Administrator in compliance with the requirements of Section 409A of the Code. 
 (b) Termination by the Company without Cause or by Awardee for Good Reason. Notwithstanding anything herein to the contrary, in the event that
such Restricted Stock Units vest prior to the Vesting Date(s) set forth in Paragraph 1 as a result of a Termination of Employment of Awardee by the Company without Cause or by Awardee for Good Reason, Awardee shall receive 

  

 2 

 
one-third of the corresponding Shares on the Date of Termination (as defined in Section 4(e) of the Employment Agreement); one-third of the
corresponding Shares on the first anniversary of the Date of Termination; and one-third of the corresponding Shares on the second anniversary of the Date of Termination, as described in the Employment Agreement without regard to the Covenants.

 (c) Death. Notwithstanding anything herein to the contrary, in the event that such Restricted Stock Units vest prior to the
Vesting Date(s) set forth in Paragraph 1 as a result of Awardee’s death, Awardee’s estate shall be entitled to receive the corresponding Shares from the Company on the date of such vesting. 
 (d) Disability. Notwithstanding anything herein to the contrary, in the event that such Restricted Stock Units vest prior to the Vesting Date(s)
set forth in Paragraph 1 as a result of the Disability of Awardee, Awardee shall be entitled to receive the corresponding Shares from the Company on the date of such vesting; provided, however, that where Section 409A of the Code
applies to such distribution and Awardee is a “specified employee” (determined in accordance with Section 409A of the Code), Awardee shall be entitled to receive the corresponding Shares from the Company on the date that is the first
day of the seventh month after Awardee’s “separation from service” with the Company (determined in accordance with Section 409A of the Code). 
 (e) Change of Control. Notwithstanding anything herein to the contrary, in the event that such Restricted Stock Units vest prior to the Vesting Date(s) set forth in Paragraph 1 as a result of the occurrence of
a Change of Control, Awardee shall be entitled to receive the corresponding Shares from the Company on the date of such vesting; provided, however, that if the Change of Control occurs under circumstances that would not qualify as a
permissible date of distribution under Section 409A(a)(2)(A) of the Code and the regulations thereunder, then Awardee shall be entitled to receive the corresponding Shares from the Company on the Vesting Date(s) that would have otherwise
applied pursuant to Paragraph 1. 
 7. Dividend Equivalents. Awardee shall not be entitled to receive any cash dividends on the
Restricted Stock Units. However, to the extent the Company determines to pay a cash dividend to holders of the Common Stock, an Awardee shall, with respect to each Restricted Stock Unit, be entitled to receive a cash payment from the Company on each
cash dividend payment date with respect to the Shares with a record date between the Grant Date and the settlement of such unit pursuant to Paragraph 6 hereof, such cash payment to be in an amount equal to the dividend that would have been paid on
the Common Stock represented by such unit. Cash payments on each cash dividend payment date with respect to the Shares with a record date prior to a Vesting Date shall be accrued until the Vesting Date and paid thereon (subject to the same vesting
requirements as the underlying Restricted Stock Units award). Elections to defer receipt of the cash payments in lieu of cash dividends beyond the date of settlement provided herein may be permitted in the discretion of the Committee pursuant to
procedures established by the Company in compliance with the requirements of Section 409A of the Code. 
 8. Right of Set-Off. By
accepting these Restricted Stock Units, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as “non-qualified deferred compensation” under Section 409A of the Code by any member
of the CareFusion Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the CareFusion Group by Awardee under this Agreement.

  

 3 

 9. No Stockholder Rights. Awardee shall have no rights of a stockholder with respect to the
Restricted Stock Units, including, without limitation, any right to vote the Shares represented by the Restricted Stock Units. 
 10.
Withholding Tax. 
 (a) Generally. Awardee is liable and responsible for all taxes owed in connection with the Restricted Stock
Units (including taxes owed with respect to any cash payments described in Paragraph 7 hereof), regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Restricted Stock Units. The
Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the grant or vesting of the Restricted Stock Units or the subsequent sale of Shares issuable upon
settlement of the Restricted Stock Units. The Company does not commit and is under no obligation to structure the Restricted Stock Units to reduce or eliminate Awardee’s tax liability. 
 (b) Payment of Withholding Taxes. Prior to any event in connection with the Restricted Stock Units (e.g., vesting or settlement) that the Company
determines may result in any domestic or foreign tax withholding obligation, whether national, federal, state or local, including any employment tax obligation (the “Tax Withholding Obligation”), Awardee is required to arrange for the
satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company. Unless Awardee elects to satisfy the Tax Withholding Obligation by an alternative means that is then permitted by the Company,
Awardee’s acceptance of this Agreement constitutes Awardee’s instruction and authorization to the Company to retain on Awardee’s behalf the number of Shares from those Shares issuable to Awardee under this Award as the Company
determines to be sufficient to satisfy the Tax Withholding Obligation as owed when any such obligation comes due. The value of any Shares retained for such purposes shall be based on the Fair Market Value, as the term is defined in the Plan, of the
Shares on the date of vesting of the Restricted Stock Units. To the extent that the Company retains any Shares to cover the Tax Withholding Obligation, it will do so at the minimum statutory rate, but in no event shall such amount exceed the minimum
required by applicable law and regulations. The Company shall have the right to deduct from all cash payments paid pursuant to Paragraph 7 hereof the amount of any taxes which the Company is required to withhold with respect to such payments.

 11. Governing Law/Venue for Dispute Resolution/Costs and Legal Fees. This Agreement shall be governed by the laws of the State of
Delaware, without regard to principles of conflicts of law, except to the extent superceded by the laws of the United States of America. The parties agree and acknowledge that the laws of the State of Delaware bear a substantial relationship to
the parties and/or this Agreement and that the Restricted Stock Units and benefits granted herein would not be granted without the governance of this Agreement by the laws of the State of Delaware. In addition, all legal actions or proceedings
relating to this Agreement shall be brought exclusively in state or federal courts located in the State of Delaware and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts. Awardee acknowledges that
the covenants 

  

 4 

 
contained in Paragraphs 4 and 5 of this Agreement are reasonable in nature, are fundamental for the protection of the Company’s legitimate business and
proprietary interests, and do not adversely affect Awardee’s ability to earn a living in any capacity that does not violate such covenants. The parties further agree that in the event of any violation by Awardee of any such covenants, the
Company will suffer immediate and irreparable injury for which there is no adequate remedy at law. In the event of any violation or attempted violations of the restrictions and covenants of Awardee contained in this Agreement, the CareFusion Group
shall be entitled to specific performance and injunctive relief or other equitable relief, including the issuance ex parte of a temporary restraining order, without any showing of irreparable harm or damage, such irreparable harm being acknowledged
and admitted by Awardee, and Awardee hereby waives any requirement for the securing or posting of any bond in connection with such remedy, without prejudice to any other rights and remedies afforded the CareFusion Group hereunder or by law. In the
event that it becomes necessary for the CareFusion Group to institute legal proceedings under this Agreement, Awardee shall be responsible to the Company for all costs and reasonable legal fees incurred by the Company with regard to such
proceedings. Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business
objectives intended by such provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement. 
 12.
Action by the Administrator. The parties agree that the interpretation of this Agreement shall rest exclusively and completely within the sole discretion of the Administrator. The parties agree to be bound by the decisions of the
Administrator with regard to the interpretation of this Agreement and with regard to any and all matters set forth in this Agreement. The Administrator may delegate its functions under this Agreement to an officer of the CareFusion Group designated
by the Administrator (hereinafter the “designee”). In fulfilling its responsibilities hereunder, the Administrator or its designee may rely upon documents, written statements of the parties or such other material as the Administrator or
its designee deems appropriate. The parties agree that there is no right to be heard or to appear before the Administrator or its designee and that any decision of the Administrator or its designee relating to this Agreement, including, without
limitation, whether particular conduct constitutes a breach of the Covenants, shall be final and binding unless such decision is arbitrary and capricious. 
 13. Prompt Acceptance of Agreement. The Restricted Stock Unit grant evidenced by this Agreement shall, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and
returned to the Company, or electronically executed by Awardee by indicating Awardee’s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company’s third-party equity plan administrator’s web
site, within 90 days of the Grant Date. 
 14. Electronic Delivery and Consent to Electronic Participation. The Company may, in its
sole discretion, decide to deliver any documents related to the Restricted Stock Unit grant under and participation in the Plan or future Restricted Stock Units that may be granted under the Plan by electronic means. Awardee hereby consents to
receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of Restricted
Stock Unit grants and the execution of Restricted Stock Unit agreements through electronic signature. 
  

 5 

 15. Notices. All notices, requests, consents and other communications required or provided under
this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage
prepaid, and will be effective upon delivery to the Company at the address set forth below: 
 CareFusion Corporation 
 3750 Torrey View Court 
 San Diego, CA 92130

 Attention: General Counsel 
 Facsimile: 858-617-2300 
 All notices, requests, consents and other communications required or provided under this Agreement to be delivered by the
Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid,
and will be effective upon delivery to the Awardee. 
 16. Employment Agreement. To the extent the Employment Agreement provides for
greater benefits to Awardee with respect to (i) the vesting of the Award or (ii) the payment of the Award than provided in this agreement or in the Plan, then the terms of the Employment Agreement, with respect to the vesting of the Award
or the price of the Award, shall supersede the terms hereof to the extent permitted by the terms of the Plan. 
  

			
	CAREFUSION CORPORATION
		
	By:	 	  

	Its:	 	  

  

 6 

 ACCEPTANCE OF AGREEMENT 
 Awardee hereby: (a) acknowledges receiving a copy of the Plan, which has either been previously delivered or is provided with this agreement, and represents that he is familiar with and understands all provisions
of the Plan and this agreement; (b) voluntarily and knowingly accepts this Agreement and the Restricted Stock Units granted to him under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in the
Agreement regarding the “Covenants” and “Special Forfeiture/Repayment Rules” set forth in Paragraphs 4 and 5 above; (c) acknowledges previously accepting, and voluntarily and knowingly accepts, the terms of the equity awards
of the Company and/or Cardinal Health, Inc. that Awardee received in connection with the spin-off of the Company from Cardinal Health, Inc., subject to all the provisions of the applicable equity incentive plan(s) under which the award(s) was
granted; and (d) represents that he understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement. Awardee further
acknowledges receiving a copy of the Company’s most recent annual report to stockholders and other communications routinely distributed to the Company’s stockholders and a copy of the Plan Prospectus dated [date of Plan Prospectus]
pertaining to the Plan. 
  

	
	  

	Awardee’s Signature
	
	  

	Date

  

 7 

 EXHIBIT C – INDEMNIFICATION AGREEMENT 
 Filed as Exhibit 10.5 to CareFusion Corporation Form 10 filed on June 26, 2009 
 At the following link: 
 http://sec.gov/Archives/edgar/data/1457543/000095012309017766/l35932a3exv10w5.htm 
  

 1 

 EXHIBIT D – RELEASE AGREEMENT 
 RELEASE AGREEMENT 
 This RELEASE AGREEMENT by and between CareFusion
Corporation (the “Company”) and David L. Schlotterbeck (the “Executive”) is dated as of the      day of         ,         
(the “Release”). 
 Release 
 Executive hereby releases the Company and any of its predecessors, successors or assigns to all or any part of its businesses (“CareFusion”) by execution of this Release from any and all claims and causes of action that may exist,
whether known or unknown, as of the date of Executive’s execution of this Release with the exception of any unemployment compensation claim Executive may have and any other claims that cannot be waived by law. Executive agrees that this Release
applies to all officers, directors, employees and other representatives of CareFusion and its affiliates and any of its predecessors, successors or assigns to all or any part of its businesses including the Company, both individually and in their
respective capacities (collectively with CareFusion, “the Releasees”). This Release relates to all causes of action to the extent permitted by law, including, but not limited to, claims under CareFusion’s policies or practices;
federal and state fair employment practices or discrimination laws; laws pertaining to breach of employment contract or wrongful termination; age discrimination claims under the Age Discrimination and Employment Act, 29 U.S.C. Section 621 et
seq., the Uniformed Services Employment and Reemployment Rights Act, 38 U.S.C. Section 4301 et seq.; the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Section 2101 et seq. and any applicable state laws of similar intent.

 In addition, Executive agrees that Executive will not initiate, bring, or prosecute any suit, action or grievance against any of the
Releasees for any released claim in any federal, state, county or municipal court, or any arbitral forum, except as specifically stated below. Executive further agree that if Executive does so, Executive will be liable for the payment of all damages
and costs, including attorneys’ fees, incurred by any of the Releasees in connection with Executive’s suit, action, or grievance. Executive also waives any right to any relief sought in connection with such claims, including any right to
damages, attorneys’ fees, costs, and all other legal or equitable relief.
 This Release and agreement not to sue does not prohibit
Executive from pursuing a lawsuit, claim, or charge to challenge the validity or enforceability of this Release under the Age Discrimination in Employment Act (“ADEA”) or the Older Workers Benefit Protection Act (“OWBPA”), nor
does it render Executive liable for damages or costs, including attorneys’ fees, incurred by the Releasees in connection with a lawsuit, claim, or charge to challenge the validity or enforceability of this Release under the ADEA or the
OWBPA. This Release and agreement not to sue also does not prohibit the Executive from filing charges with government agencies or participating in any investigation resulting from such charges. However, under this Release, Executive agrees
not to accept any monetary or personal relief or remedy, including but not limited to back pay, front pay, or reinstatement, that may be awarded to Executive in connection with such charges. In addition, this general release is not intended to
bar any claims for workers’ compensation benefits.
  

 1 

 This Release does not apply to any claims arising after Executive’s execution of this Release or any
claims relating to rights under the Employment Agreement by and between CareFusion Corporation, a Delaware corporation, and the Executive, dated as of the      day of July 2009, as may be amended from time to time. 
 Complete Release 
 Executive also expressly agrees
that Executive has read, understands, and intends to waive any and all rights or benefits described in Section 1542 of the California Civil Code, which provides as follows: 
 “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release,
which if known by him must have materially affected his settlement with the debtor.” 
 Thus, notwithstanding the provisions of Section 1542, and
for the express purpose of implementing a full and complete release and discharge of CareFusion and any of its predecessors, successors or assigns to all or any part of its businesses, Executive expressly acknowledge that this Release is intended to
include within its effect, without limitation, all claims Executive does not know or suspect to exist in Executive’s favor at the time of execution of this Release, and this Release contemplates the extinguishment of any such claim(s).

 IN WITNESS WHEREOF, the Executive has hereunto set the Executive’s hand and the Company has caused this Release to be executed in its
name on its behalf, all as of the day and year first above written. 
  

			
	  

	David L. Schlotterbeck
	Date:	 	
	
	CAREFUSION CORPORATION
		
	By	 	  

	Name:	 	
	Title:	 	Chair, Human Resources and Compensation Committee
	Date:	 	

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]